|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases abundance multiple interactions |
ISO |
PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha |
CTD |
PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 results in increased expression of CXCL2 protein 13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of CXCL2 mRNA] |
CTD |
PMID:21094227 PMID:21735453 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of GATA3 mRNA] |
CTD |
PMID:21735453 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of IL4 protein] |
CTD |
PMID:21735453 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR protein; 13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO EXP |
13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] 13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein] |
CTD |
PMID:12721327 PMID:15528449 PMID:16256979 |
|
NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases abundance multiple interactions |
ISO |
PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2 [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E2] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2 |
CTD |
PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases abundance multiple interactions |
ISO |
PTGR1 protein results in increased abundance of 13,14-dihydro-15-ketoprostaglandin E1 [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E] which results in increased abundance of 13,14-dihydro-15-ketoprostaglandin E1 |
CTD |
PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression multiple interactions |
EXP |
9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
multiple interactions increases expression |
EXP |
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]; NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of NGF mRNA] |
CTD |
PMID:22982731 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
increases chemical synthesis |
ISO |
HPGD protein results in increased chemical synthesis of 15-ketoprostaglandin E2 |
CTD |
PMID:20448048 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions increases metabolic processing increases reduction |
EXP ISO |
15-ketoprostaglandin E2 inhibits the reaction [PTGR1 protein results in increased reduction of 10-nitro-oleic acid analog]; Dithionitrobenzoic Acid inhibits the reaction [PTGR1 protein results in increased reduction of 15-ketoprostaglandin E2]; Indomethacin inhibits the reaction [PTGR1 protein results in increased reduction of 15-ketoprostaglandin E2] [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E2] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2 |
CTD |
PMID:23878198 PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects export affects glutathionylation increases transport |
ISO |
[ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] ABCC1 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog ABCC1 protein affects the glutathionylation of 15-deoxy-delta(12,14)-prostaglandin J2 |
CTD |
PMID:14979731 PMID:21728338 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
affects export |
ISO |
ABCC3 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog |
CTD |
PMID:14979731 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA |
CTD |
PMID:34323617 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA |
CTD |
PMID:34323617 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:18278065 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2 |
CTD |
PMID:19997560 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BGLAP mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC2 protein |
CTD |
PMID:15498850 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC3 protein |
CTD |
PMID:15498850 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of CASP3 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of CASP3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:11785780 PMID:15498850 PMID:16299251 PMID:23973622 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP8 protein |
CTD |
PMID:15498850 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:15498850 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] |
CTD |
PMID:12847270 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein] |
CTD |
PMID:15187150 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA] |
CTD |
PMID:23688403 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] |
CTD |
PMID:19429239 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNA2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd3 |
cyclin D3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCND3 protein |
CTD |
PMID:15729575 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNE1 protein |
CTD |
PMID:15729575 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDK2 protein |
CTD |
PMID:15729575 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CDKN1A 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1A protein |
CTD |
PMID:15254749 PMID:15729575 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1B protein |
CTD |
PMID:15729575 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CEBPA mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CFLAR protein |
CTD |
PMID:15498850 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of CHUK protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased phosphorylation of CHUK protein] |
CTD |
PMID:15498850 PMID:22245093 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 4:146,569,288...146,582,173
Ensembl chr 4:146,569,289...146,582,173
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of COL1A1 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] |
CTD |
PMID:12604364 PMID:14998300 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased activity of EGR1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of EGR1 mRNA] |
CTD |
PMID:12468449 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Tretinoin] results in increased expression of FABP4 mRNA [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FABP4 mRNA |
CTD |
PMID:9543393 PMID:12021203 PMID:16573735 PMID:34323617 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of FAS mRNA |
CTD |
PMID:16712844 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; wortmannin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA] |
CTD |
PMID:11457450 PMID:11687581 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; [ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein |
CTD |
PMID:21728338 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression decreases expression multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GFAP 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of GFAP mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA] |
CTD |
PMID:15254749 PMID:15994020 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
GSTM1 protein affects the metabolism of [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Glutathione] |
CTD |
PMID:14979731 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein] |
CTD |
PMID:11600134 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hdac1 |
histone deacetylase 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC1 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC2 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC3 mRNA |
CTD |
PMID:21957481 |
|
NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
affects stability multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 affects the stability of HIF1A protein Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Dithiothreitol inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein] |
CTD |
PMID:17658243 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein; [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] ochratoxin A inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 protein |
CTD |
PMID:11078701 PMID:15618017 PMID:15994020 PMID:19136476 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions increases activity |
ISO |
HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of HSF1 protein |
CTD |
PMID:15618017 PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HSPB1 protein |
CTD |
PMID:16299251 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases expression decreases secretion |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IFNG protein |
CTD |
PMID:12847270 PMID:16844232 PMID:19888466 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA] |
CTD |
PMID:14998300 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression decreases activity |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in decreased abundance of Prostaglandins]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1B protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with IL1B protein] results in decreased secretion of IL1B protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of IL1B protein |
CTD |
PMID:11457450 PMID:12604364 PMID:14998300 PMID:15751073 PMID:16461118 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
decreases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1RN mRNA |
CTD |
PMID:15751073 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2] |
CTD |
PMID:23688403 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:12604364 PMID:12847270 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ACAA2 mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of ADIPOQ mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of CIDEC mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of FABP4 mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PLIN1 mRNA; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARA mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of INS mRNA] |
CTD |
PMID:14625208 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf1 |
interferon regulatory factor 1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA] |
CTD |
PMID:12847270 |
|
NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]] |
CTD |
PMID:12847270 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein] |
CTD |
PMID:11457450 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Lep |
leptin |
multiple interactions increases secretion |
ISO |
[Dexamethasone co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased secretion of LEP protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased secretion of LEP protein |
CTD |
PMID:11092516 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:19922793 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of LPL mRNA |
CTD |
PMID:12021203 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK1 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK1 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK3 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK3 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11687581 PMID:12083801 PMID:16611854 PMID:19888466 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Med1 |
mediator complex subunit 1 |
multiple interactions |
ISO |
MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] |
CTD |
PMID:16324150 |
|
NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Dactinomycin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] |
CTD |
PMID:19136476 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of MMP9 mRNA] |
CTD |
PMID:19997048 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MTOR protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nes |
nestin |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NES protein |
CTD |
PMID:15212945 |
|
NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased activity of NFE2L2 protein; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of NFE2L2 protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and affects the localization of NFE2L2 protein; manganese chloride inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NFE2L2 protein] |
CTD |
PMID:19136476 PMID:21728338 PMID:22245093 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions decreases localization |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased localization of NFKB1 protein |
CTD |
PMID:11457450 PMID:16299251 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases phosphorylation |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased degradation of NFKBIA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:15498850 PMID:22245093 PMID:23688403 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA] |
CTD |
PMID:11457450 PMID:11890746 PMID:12847270 PMID:15684285 PMID:15994020 PMID:16461118 PMID:19997048 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases activity |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS3 protein |
CTD |
PMID:11890746 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
affects activity multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 affects the activity of NR3C1 protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Dexamethasone binds to NR3C1 protein] |
CTD |
PMID:15187150 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 protein] |
CTD |
PMID:22245093 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of PARP1 protein [delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of PARP1 protein |
CTD |
PMID:15498850 PMID:23973622 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PCK1 mRNA |
CTD |
PMID:9518257 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PLIN1 mRNA |
CTD |
PMID:34323617 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARA protein [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS1 protein] results in increased expression of PPARA mRNA |
CTD |
PMID:9013583 PMID:34323617 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARD protein |
CTD |
PMID:17341418 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression decreases response to substance increases expression increases activity multiple interactions decreases expression |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 affects the expression of PPARG PPARG protein mutant form results in decreased susceptibility to 15-deoxy-delta(12,14)-prostaglandin J2 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] 15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased expression of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in decreased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased localization of and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [deoxynivalenol results in increased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of PPARG mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; MG 262 promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PPARG protein |
CTD |
PMID:9013583 PMID:10662598 PMID:11030710 PMID:12065695 PMID:12604364 PMID:12839938 PMID:12847270 PMID:14625208 PMID:14979731 PMID:14998300 PMID:15212945 PMID:15254749 PMID:15322177 PMID:15491415 PMID:15707588 PMID:15729575 PMID:15866424 PMID:15994020 PMID:16324150 PMID:16499875 PMID:17341418 PMID:18278065 PMID:18485432 PMID:19922793 PMID:23943857 PMID:26172262 PMID:30138673 More...
|
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in increased expression of PTEN protein |
CTD |
PMID:16611854 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] |
CTD |
PMID:12721327 PMID:16256979 |
|
NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
PTGS1 protein promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2] |
CTD |
PMID:17439952 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PTGS2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PTGS2 |
CTD |
PMID:11457450 PMID:12604364 PMID:15254749 PMID:19997048 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn11 |
protein tyrosine phosphatase, non-receptor type 11 |
increases phosphorylation |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of PTPN11 protein |
CTD |
PMID:12584205 |
|
NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of and results in decreased phosphorylation of RAF1 protein |
CTD |
PMID:12083801 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rarb |
retinoic acid receptor, beta |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RARB |
CTD |
PMID:12839938 PMID:15254749 |
|
NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of and results in decreased expression of RB1 protein |
CTD |
PMID:15729575 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases activity |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of RELA protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride affects the localization of RELA protein] |
CTD |
PMID:11457450 PMID:15498850 PMID:20174873 PMID:22245093 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rig1 |
RNA sensor RIG-1 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of RIGI mRNA] |
CTD |
PMID:16303604 |
|
NCBI chr 5:55,321,351...55,369,947
Ensembl chr 5:55,321,235...55,370,819
|
|
G |
Rps6ka1 |
ribosomal protein S6 kinase A1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of RPS6KA1 protein |
CTD |
PMID:16611854 |
|
NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] |
CTD |
PMID:16611854 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of RUNX2 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Rxra |
retinoid X receptor alpha |
increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RXRA |
CTD |
PMID:15254749 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] |
CTD |
PMID:18278065 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] |
CTD |
PMID:19429239 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Socs1 |
suppressor of cytokine signaling 1 |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS1 mRNA |
CTD |
PMID:12584205 |
|
NCBI chr10:4,882,651...4,884,342
Ensembl chr10:4,882,560...4,884,383
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS3 mRNA |
CTD |
PMID:12584205 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of SPP1 mRNA |
CTD |
PMID:12021203 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [peroxyvanadate results in increased phosphorylation of STAT1 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] |
CTD |
PMID:12584205 PMID:12847270 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein] 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:12584205 PMID:12847270 PMID:19922793 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions decreases expression |
ISO |
PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] |
CTD |
PMID:16499875 |
|
NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176
|
|
G |
Tg |
thyroglobulin |
multiple interactions increases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TG protein |
CTD |
PMID:11078701 |
|
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression decreases response to substance |
ISO EXP |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TGFB1 mRNA 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein] 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [alitretinoin results in decreased expression of TGFB1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased susceptibility to TGFB1 protein |
CTD |
PMID:16611854 PMID:18278065 PMID:19429239 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
increases expression |
EXP |
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TH protein |
CTD |
PMID:15212945 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 mRNA] 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TLR2 mRNA |
CTD |
PMID:20174873 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TNF protein 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:12604364 PMID:19888466 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] |
CTD |
PMID:11078701 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] |
CTD |
PMID:23688403 |
|
NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of VIM |
CTD |
PMID:15254749 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wnt10b |
Wnt family member 10B |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of WNT10B mRNA |
CTD |
PMID:12021203 |
|
NCBI chr 7:129,922,088...129,927,892
Ensembl chr 7:129,922,088...129,927,892
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of XIAP protein |
CTD |
PMID:15498850 PMID:16299251 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases metabolic processing multiple interactions |
ISO |
PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha [PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha |
CTD |
PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Agt |
angiotensinogen |
increases abundance multiple interactions |
EXP |
AGT protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha Dexamethasone inhibits the reaction [AGT protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:4030047 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
ISO |
[ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:21193584 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Apoe |
apolipoprotein E |
increases abundance multiple interactions |
ISO |
APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha nimesulide inhibits the reaction [APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:14966570 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Avp |
arginine vasopressin |
increases abundance multiple interactions |
EXP |
AVP protein results in increased abundance of 6-Ketoprostaglandin F1 alpha Dexamethasone inhibits the reaction [AVP protein results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:4030047 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects abundance multiple interactions |
ISO EXP |
BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha [kallidin, des-Arg(10)- binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha; [KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha PD 123319 affects the reaction [BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:16514058 PMID:29775649 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
decreases abundance increases abundance |
ISO EXP |
CALCA protein alternative form results in decreased abundance of 6-Ketoprostaglandin F1 alpha CALCA protein results in increased abundance of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:12024109 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Klkb1 |
kallikrein B1 |
multiple interactions increases abundance |
ISO |
7-Ala-angiotensin (1-7) inhibits the reaction [KLKB1 gene mutant form results in increased abundance of 6-Ketoprostaglandin F1 alpha]; nimesulide inhibits the reaction [KLKB1 gene mutant form results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:25339356 |
|
NCBI chr16:46,958,634...46,982,054
Ensembl chr16:46,958,707...46,982,053
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions increases abundance |
EXP |
[KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha; Dexamethasone inhibits the reaction [KNG1 protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:4030047 PMID:29775649 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:16325209 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ptgis |
prostaglandin I2 synthase |
multiple interactions increases chemical synthesis |
EXP |
[Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha PTGIS protein results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:19491382 |
|
NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:155,916,412...155,965,451
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha]; S-methylisothiopseudouronium inhibits the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:16325209 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tnf |
tumor necrosis factor |
increases abundance |
ISO |
TNF protein results in increased abundance of 6-Ketoprostaglandin F1 alpha |
CTD |
PMID:1993070 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
affects response to substance |
ISO |
PTGER4 protein affects the susceptibility to 8-isoprostaglandin E2 |
CTD |
PMID:22565502 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased abundance of 8-epi-prostaglandin F2alpha |
CTD |
PMID:17118406 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases abundance |
ISO |
[Lead co-treated with APP protein modified form] results in increased abundance of 8-epi-prostaglandin F2alpha APP protein modified form results in increased abundance of 8-epi-prostaglandin F2alpha |
CTD |
PMID:22610977 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance increases chemical synthesis |
ISO EXP |
1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]]; Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Dehydroascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Indomethacin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; resveratrol inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] pyrrolidine dithiocarbamic acid inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha]; Rotenone inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha] |
CTD |
PMID:11530235 PMID:16529823 PMID:19751497 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Pafah2 |
platelet-activating factor acetylhydrolase 2 |
affects metabolic processing multiple interactions |
ISO |
PAFAH2 protein affects the metabolism of 8-epi-prostaglandin F2alpha PAFAH2 protein affects the reaction [Carbon Tetrachloride results in increased abundance of 8-epi-prostaglandin F2alpha] |
CTD |
PMID:18024956 |
|
NCBI chr 5:146,607,050...146,636,203
Ensembl chr 5:146,613,498...146,634,943
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[L 745337 results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of 8-epi-prostaglandin F2alpha; [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha |
CTD |
PMID:8621535 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tbxa2r |
thromboxane A2 receptor |
multiple interactions affects response to substance |
ISO |
8-epi-prostaglandin F2alpha binds to and results in increased activity of TBXA2R protein TBXA2R protein affects the susceptibility to 8-epi-prostaglandin F2alpha |
CTD |
PMID:18158556 PMID:22565502 |
|
NCBI chr 7:8,383,347...8,390,753
Ensembl chr 7:8,383,378...8,388,176
|
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
fluprostenol inhibits the reaction [Niacin results in increased expression of FABP4 mRNA] |
CTD |
PMID:21236357 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
decreases expression |
EXP |
fluprostenol results in decreased expression of FGFR2 mRNA |
CTD |
PMID:15654655 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
fluprostenol promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein] fluprostenol results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:33486071 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
fluprostenol promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein] fluprostenol results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:33486071 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
fluprostenol inhibits the reaction [Niacin results in increased expression of PPARG mRNA] |
CTD |
PMID:21236357 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgfr |
prostaglandin F receptor |
multiple interactions |
ISO |
PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr 2:240,731,185...240,766,674
Ensembl chr 2:240,733,375...240,765,650
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]] |
CTD |
PMID:33486071 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity |
ISO |
latanoprost results in decreased activity of ABCB11 protein |
CTD |
PMID:23956101 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
|
G |
Aars1 |
alanyl-tRNA synthetase 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of AARS1 protein |
CTD |
PMID:19800325 |
|
NCBI chr19:38,999,130...39,021,152
Ensembl chr19:38,999,163...39,021,147
|
|
G |
Actn1 |
actinin, alpha 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of ACTN1 protein |
CTD |
PMID:19800325 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Actn3 |
actinin alpha 3 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of ACTN3 protein |
CTD |
PMID:19800325 |
|
NCBI chr 1:202,159,081...202,175,012
Ensembl chr 1:202,159,082...202,175,012
|
|
G |
Actn4 |
actinin alpha 4 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of ACTN4 protein |
CTD |
PMID:19800325 |
|
NCBI chr 1:84,182,783...84,251,867
Ensembl chr 1:84,182,788...84,251,847
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
EXP |
prostaglandin A1 promotes the reaction [arsenite results in increased expression of CRYAB mRNA]; prostaglandin A1 promotes the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:9066782 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of EEF1A1 protein |
CTD |
PMID:19800325 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of EEF2 protein |
CTD |
PMID:19800325 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Eno1 |
enolase 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of ENO1 protein |
CTD |
PMID:19800325 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of GAPDH protein |
CTD |
PMID:19800325 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gpi |
glucose-6-phosphate isomerase |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of GPI1 protein |
CTD |
PMID:19800325 |
|
NCBI chr 1:86,828,211...86,856,077
Ensembl chr 1:86,828,216...86,856,086
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of HMGCS1 protein |
CTD |
PMID:19800325 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
prostaglandin A1 analog results in increased expression of HMOX1 protein; prostaglandin A1 results in increased expression of HMOX1 protein |
CTD |
PMID:19800325 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of HSP90AA1 protein |
CTD |
PMID:19800325 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of HSP90AB1 protein |
CTD |
PMID:19800325 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of HSP90B1 protein |
CTD |
PMID:19800325 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of HSPA4 protein |
CTD |
PMID:19800325 |
|
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of HSPA8 protein |
CTD |
PMID:19800325 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of HSPH1 protein |
CTD |
PMID:19800325 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of IDH2 protein |
CTD |
PMID:19800325 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ipo7 |
importin 7 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of IPO7 protein |
CTD |
PMID:19800325 |
|
NCBI chr 1:164,062,702...164,102,938
Ensembl chr 1:164,062,702...164,102,938
|
|
G |
Ldha |
lactate dehydrogenase A |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of LDHA protein |
CTD |
PMID:19800325 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
prostaglandin A1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] |
CTD |
PMID:12031542 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npepps |
aminopeptidase puromycin sensitive |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of NPEPPS protein |
CTD |
PMID:19800325 |
|
NCBI chr10:82,191,454...82,273,967
Ensembl chr10:82,191,456...82,273,967
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of PGK1 protein |
CTD |
PMID:19800325 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Pgm1 |
phosphoglucomutase 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of PGM1 protein |
CTD |
PMID:19800325 |
|
NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728
|
|
G |
Phgdh |
phosphoglycerate dehydrogenase |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of PHGDH protein |
CTD |
PMID:19800325 |
|
NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of PSAT1 protein |
CTD |
PMID:19800325 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
prostaglandin A1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:12031542 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rack1 |
receptor for activated C kinase 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of RACK1 protein |
CTD |
PMID:19800325 |
|
NCBI chr10:33,169,415...33,174,896
Ensembl chr10:33,169,169...33,174,975
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of TUBB5 protein |
CTD |
PMID:19800325 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Uba1 |
ubiquitin-like modifier activating enzyme 1 |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of UBA1 protein |
CTD |
PMID:19800325 |
|
NCBI chr X:1,508,700...1,530,677
Ensembl chr X:1,508,666...1,530,636
|
|
G |
Vcp |
valosin-containing protein |
increases metabolic processing |
ISO |
prostaglandin A1 analog results in increased metabolism of VCP protein |
CTD |
PMID:19800325 |
|
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
|
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
EXP |
prostaglandin A2 promotes the reaction [arsenite results in increased expression of CRYAB mRNA]; prostaglandin A2 promotes the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:9066782 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
affects metabolic processing |
ISO |
GSTA1 protein affects the metabolism of prostaglandin A2 |
CTD |
PMID:9084911 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
affects metabolic processing |
ISO |
GSTA2 protein affects the metabolism of prostaglandin A2 |
CTD |
PMID:9084911 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
affects metabolic processing |
ISO |
GSTM1 protein affects the metabolism of prostaglandin A2 |
CTD |
PMID:9084911 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Tnf |
tumor necrosis factor |
increases abundance |
ISO |
TNF protein results in increased abundance of prostaglandin A2 |
CTD |
PMID:1993070 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of prostaglandin B1 |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of prostaglandin B1 |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of prostaglandin B1 |
CTD |
PMID:15231852 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases metabolic processing increases reduction decreases response to substance decreases metabolic processing multiple interactions |
ISO |
AKR1C3 protein results in increased metabolism of Prostaglandin D2 AKR1C3 protein results in increased reduction of Prostaglandin D2 AKR1C3 protein results in decreased susceptibility to Prostaglandin D2 AKR1C3 protein results in decreased metabolism of Prostaglandin D2 [AKR1C3 protein results in decreased metabolism of Prostaglandin D2] which results in decreased chemical synthesis of 9-deoxy-delta-9-prostaglandin D2; [AKR1C3 protein results in increased reduction of Prostaglandin D2] which results in increased chemical synthesis of Dinoprost; [Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost] |
CTD |
PMID:19010312 PMID:19997560 PMID:20036328 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
App |
amyloid beta precursor protein |
increases secretion multiple interactions |
ISO |
APP protein modified form results in increased secretion of Prostaglandin D2 CNB 001 inhibits the reaction [APP protein modified form results in increased secretion of Prostaglandin D2]; Dronabinol inhibits the reaction [APP protein modified form results in increased secretion of Prostaglandin D2]; L 685458 inhibits the reaction [APP protein modified form results in increased secretion of Prostaglandin D2] |
CTD |
PMID:28721267 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases cleavage |
ISO |
Prostaglandin D2 results in increased cleavage of ARHGDIB protein |
CTD |
PMID:15843042 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage |
ISO EXP |
Prostaglandin D2 results in increased activity of CASP3 protein Prostaglandin D2 results in increased cleavage of CASP3 protein |
CTD |
PMID:15843042 PMID:23973622 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
EXP |
Prostaglandin D2 promotes the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:9066782 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of CXCL2 protein; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of CXCL2 protein] Prostaglandin D2 results in increased expression of CXCL2 protein |
CTD |
PMID:21166666 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[EGF protein co-treated with Prostaglandin D2] results in increased expression of MYC mRNA |
CTD |
PMID:12632255 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
ISO |
EPHX2 gene mutant form promotes the reaction [Aspirin inhibits the reaction [Lipopolysaccharides results in increased abundance of Prostaglandin D2]] |
CTD |
PMID:19896470 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
ISO |
Prostaglandin D2 results in increased expression of FABP4 mRNA |
CTD |
PMID:9543393 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Hpgds |
hematopoietic prostaglandin D synthase |
multiple interactions |
ISO |
[4-benzhydryloxy-1-(3-(1H-tetrazol-5-yl-)-propyl)piperidine results in increased expression of HPGDS mRNA] which results in decreased abundance of Prostaglandin D2 |
CTD |
PMID:21352547 |
|
NCBI chr 4:94,368,426...94,397,931
Ensembl chr 4:94,373,342...94,397,883
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance increases expression increases secretion |
ISO EXP |
[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Prostaglandin D2; Indomethacin inhibits the reaction [[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Prostaglandin D2]; resveratrol inhibits the reaction [IL1B protein results in increased abundance of Prostaglandin D2] Prostaglandin D2 results in increased expression of IL1B protein [Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL1B protein; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL1B protein] IL1B protein results in increased secretion of Prostaglandin D2 IL1B protein promotes the reaction [rosiglitazone results in increased secretion of Prostaglandin D2] |
CTD |
PMID:12743569 PMID:12897060 PMID:19751497 PMID:21166666 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of Prostaglandin D2] |
CTD |
PMID:23688403 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL6 protein; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL6 protein] |
CTD |
PMID:21166666 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lypla2 |
lysophospholipase 2 |
increases hydrolysis |
ISO |
LYPLA2 protein results in increased hydrolysis of Prostaglandin D2 analog |
CTD |
PMID:25301951 |
|
NCBI chr 5:148,198,466...148,203,062
Ensembl chr 5:148,198,439...148,203,092
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Prostaglandin D2 results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:24813642 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Prostaglandin D2 results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:24813642 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
EXP |
[EGF protein co-treated with Prostaglandin D2] results in increased expression of MYC mRNA |
CTD |
PMID:12632255 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO EXP |
Prostaglandin D2 results in increased cleavage of PARP1 protein |
CTD |
PMID:15843042 PMID:23973622 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions affects localization |
ISO |
Prostaglandin D2 affects the localization of and results in increased expression of PPARG protein Prostaglandin D2 affects the localization of PPARG protein |
CTD |
PMID:23220503 PMID:23943857 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Prostaglandin D2 results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
increases phosphorylation |
ISO |
Prostaglandin D2 results in increased phosphorylation of PPP1R12A protein |
CTD |
PMID:24813642 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; 9-deoxy-delta-9-prostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; adenosine 5'-O-(3-thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Adenylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Alprostadil inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; BW 245C inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; BW A868C inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; delta(12)-prostaglandin J(2) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Dinoprost inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Dinoprostone inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Guanosine 5'-O-(3-Thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Guanylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Iloprost inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; L 644698 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein]; Prostaglandin D2 binds to and results in increased activity of PTGDR protein; ZK 110841 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] [Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased metabolism of Adenosine; [Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased secretion of Adenosine; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of CXCL2 protein]; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL1B protein]; PTGDR protein promotes the reaction [[Lipopolysaccharides results in increased abundance of Prostaglandin D2] which results in increased expression of IL6 protein] |
CTD |
PMID:9579725 PMID:11562489 PMID:21166666 PMID:27636113 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Ptgdr2 |
prostaglandin D2 receptor 2 |
multiple interactions increases activity affects binding |
ISO |
Endocannabinoids inhibits the reaction [Prostaglandin D2 binds to and results in increased activity of PTGDR2 protein]; Prostaglandin D2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [Prostaglandin D2 binds to and results in increased activity of PTGDR2 protein] Prostaglandin D2 results in increased activity of PTGDR2 protein 13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; 5-hydroxyindomethacin inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; Indomethacin inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; ramatroban inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; sulindac sulfide inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]; zomepirac inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein] |
CTD |
PMID:11801628 PMID:12721327 PMID:15563582 PMID:16256979 PMID:21916510 PMID:30102254 More...
|
|
NCBI chr 1:207,585,088...207,590,275
Ensembl chr 1:207,587,917...207,589,213
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions |
ISO |
Prostaglandin D2 binds to and results in increased activity of PTGER2 protein |
CTD |
PMID:27636113 |
|
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [2-phenylphenol binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [Acetaminophen results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Prostaglandin D2; [Chlorpropham binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [cypermethrin binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [cyprodinil binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [enilconazole binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [fludioxonil binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [Ibuprofen binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [Linuron binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [Methiocarb binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [Nanotubes, Carbon co-treated with PTGS2 gene mutant form] results in increased abundance of Prostaglandin D2; [pirimiphos methyl binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Prostaglandin D2; [PTGS2 gene mutant form results in increased susceptibility to Nanotubes, Carbon] which results in increased abundance of Prostaglandin D2; [pyrimethanil binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2; [tebuconazole binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 |
CTD |
PMID:11743745 PMID:18834901 PMID:23642096 PMID:26359731 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rorc |
RAR-related orphan receptor C |
increases expression |
ISO |
Prostaglandin D2 results in increased expression of RORC mRNA |
CTD |
PMID:9543393 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Slc22a22 |
solute carrier family 22 member 22 |
affects binding |
ISO |
Prostaglandin D2 binds to SLC22A22 protein |
CTD |
PMID:20448048 |
|
NCBI chr 7:88,720,425...88,750,111
Ensembl chr 7:88,720,427...88,750,111
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Prostaglandin D2 promotes the reaction [Kallidin results in increased secretion of TAC1 protein] |
CTD |
PMID:16039053 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tg |
thyroglobulin |
multiple interactions increases expression |
ISO |
Prostaglandin D2 promotes the reaction [TSHB protein results in increased expression of TG protein] Prostaglandin D2 results in increased expression of TG protein |
CTD |
PMID:11078701 |
|
NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases response to substance |
ISO |
Prostaglandin D2 results in decreased susceptibility to TGFB1 protein |
CTD |
PMID:20719937 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance |
ISO |
[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Prostaglandin D2; Indomethacin inhibits the reaction [[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Prostaglandin D2] TNF protein results in increased abundance of Prostaglandin D2 |
CTD |
PMID:1993070 PMID:12743569 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression increases secretion multiple interactions |
ISO |
Prostaglandin D2 results in increased expression of TNFRSF11B mRNA Prostaglandin D2 results in increased secretion of TNFRSF11B protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein]; resveratrol inhibits the reaction [Prostaglandin D2 results in increased expression of TNFRSF11B mRNA]; resveratrol inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein]; SRT1720 inhibits the reaction [Prostaglandin D2 results in increased expression of TNFRSF11B mRNA]; SRT1720 inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein] |
CTD |
PMID:24813642 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
Prostaglandin D2 promotes the reaction [TSHB protein results in increased expression of TG protein] |
CTD |
PMID:11078701 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Ucp2 |
uncoupling protein 2 |
affects chemical synthesis |
ISO |
UCP2 protein affects the chemical synthesis of Prostaglandin D2 |
CTD |
PMID:19846869 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
prostaglandin D3 promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:12573452 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
prostaglandin D3 promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:12573452 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
Quercetin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]; Silymarin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]] |
CTD |
PMID:16156793 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases phosphorylation |
ISO |
Alprostadil results in increased phosphorylation of ADRB2 protein |
CTD |
PMID:14722251 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Agt |
angiotensinogen |
increases expression |
ISO |
Alprostadil results in increased expression of AGT protein |
CTD |
PMID:9195357 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Alprostadil inhibits the reaction [Galactosamine results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:15565661 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Alprostadil inhibits the reaction [[Phenytoin co-treated with Buthionine Sulfoximine] results in increased expression of CXCL2 mRNA]; Alprostadil inhibits the reaction [Carbamazepine results in increased expression of CXCL2 mRNA] |
CTD |
PMID:22790970 PMID:23986454 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
Alprostadil inhibits the reaction [Carbamazepine results in increased expression of IL23A mRNA] |
CTD |
PMID:22790970 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
EXP ISO |
Alprostadil results in increased expression of IL6 protein Alprostadil inhibits the reaction [Carbamazepine results in increased expression of IL6 mRNA] Dexamethasone inhibits the reaction [Alprostadil results in increased expression of IL6 protein] |
CTD |
PMID:7536779 PMID:22790970 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in decreased expression of NFKBIA protein]] |
CTD |
PMID:15565661 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
EXP |
Alprostadil results in increased expression of NOS2 mRNA; Alprostadil results in increased expression of NOS2 promoter; Alprostadil results in increased expression of NOS2 protein Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 mRNA]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 promoter]; Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]; Enzyme Inhibitors inhibits the reaction [Alprostadil inhibits the reaction [Galactosamine results in increased expression of NOS2 protein]]; Galactosamine promotes the reaction [Alprostadil results in increased expression of NOS2 protein] |
CTD |
PMID:15189274 PMID:15565661 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
ISO |
Alprostadil results in decreased expression of NPPA protein |
CTD |
PMID:10506854 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
ISO |
Alprostadil results in decreased expression of NPPB protein |
CTD |
PMID:16084762 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
affects binding multiple interactions |
ISO |
Alprostadil binds to PTGDR protein Alprostadil inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Alprostadil results in increased localization of and results in increased activity of RELA protein |
CTD |
PMID:15189274 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
increases expression |
ISO |
Alprostadil results in increased expression of REN protein |
CTD |
PMID:9195357 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression |
EXP |
Alprostadil results in decreased expression of TIMP1 |
CTD |
PMID:16859129 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression decreases secretion |
ISO EXP |
Alprostadil inhibits the reaction [Lipopolysaccharides results in increased expression of TNF] Alprostadil results in decreased expression of TNF protein Alprostadil promotes the reaction [Galactosamine results in increased expression of TNF protein] Alprostadil results in decreased secretion of TNF protein |
CTD |
PMID:7536779 PMID:7956562 PMID:9298541 PMID:10221824 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases secretion multiple interactions increases expression |
ISO |
Alprostadil results in increased secretion of TNFRSF11B protein pyrazolanthrone inhibits the reaction [Alprostadil results in increased secretion of TNFRSF11B protein]; resveratrol inhibits the reaction [Alprostadil results in increased expression of TNFRSF11B mRNA]; resveratrol inhibits the reaction [Alprostadil results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Alprostadil results in increased secretion of TNFRSF11B protein]; SRT1720 inhibits the reaction [Alprostadil results in increased secretion of TNFRSF11B protein] |
CTD |
PMID:25677506 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation |
ISO |
Alprostadil results in increased phosphorylation of VASP protein |
CTD |
PMID:20129490 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases export affects export |
ISO |
ABCC4 protein results in increased export of Dinoprostone ABCC4 gene SNP affects the export of Dinoprostone |
CTD |
PMID:22155354 PMID:27659809 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
ISO |
ACE inhibits the reaction [Cocaine affects the abundance of Dinoprostone] |
CTD |
PMID:14738173 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
multiple interactions decreases expression |
EXP |
4-(4-cyano-2-(2-(4-fluoronaphthalen-1-yl)propionylamino)phenyl)butyric acid inhibits the reaction [Dinoprostone results in decreased expression of ACTA1 mRNA] |
CTD |
PMID:18030065 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
ISO |
Dinoprostone results in increased expression of ACTA2 protein |
CTD |
PMID:27697457 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
EXP |
Dinoprostone inhibits the reaction [ADCYAP1 protein results in increased secretion of Histamine] |
CTD |
PMID:11164953 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adm |
adrenomedullin |
decreases expression |
ISO |
Dinoprostone results in decreased expression of ADM mRNA |
CTD |
PMID:19253104 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone] |
CTD |
PMID:17369603 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases abundance |
EXP |
Dexamethasone inhibits the reaction [AGT protein alternative form results in increased abundance of Dinoprostone] |
CTD |
PMID:4030047 PMID:6421564 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
multiple interactions |
ISO |
[sorbinil results in decreased activity of AKR1B1 protein] inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]; [zopolrestat results in decreased activity of AKR1B1 protein] inhibits the reaction [Antigens, Plant results in increased secretion of Dinoprostone] |
CTD |
PMID:21334316 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation decreases phosphorylation multiple interactions |
ISO EXP |
Dinoprostone results in increased phosphorylation of AKT1 protein Dinoprostone results in decreased phosphorylation of AKT1 protein taiwanin C inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein] Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased activity of AKT1 protein]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein] Dinoprostone results in increased phosphorylation of and results in increased activity of AKT1 protein; oxodiperoxo(pyridine-2-carboxylate)vanadate(V) inhibits the reaction [Dinoprostone results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16396944 PMID:17805209 PMID:18056380 PMID:23747687 PMID:25094029 PMID:30884126 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
ISO |
[ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of Dinoprostone |
CTD |
PMID:21193584 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
ISO |
ANXA1 protein inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone] |
CTD |
PMID:21777521 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
EXP |
Dinoprostone inhibits the reaction [Carbon Tetrachloride results in increased expression of APOA1 mRNA] |
CTD |
PMID:15816358 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
App |
amyloid beta precursor protein |
increases abundance multiple interactions increases secretion increases expression |
EXP ISO |
APP protein modified form results in increased abundance of Dinoprostone CNB 001 inhibits the reaction [APP protein modified form results in increased secretion of Dinoprostone]; Dronabinol inhibits the reaction [APP protein modified form results in increased secretion of Dinoprostone]; L 685458 inhibits the reaction [APP protein modified form results in increased secretion of Dinoprostone] [APP protein binds to APP protein binds to APP protein] which results in increased abundance of Dinoprostone; neoechinulin A inhibits the reaction [[APP protein binds to APP protein binds to APP protein] which results in increased abundance of Dinoprostone] PTGES2 promotes the reaction [APP protein modified form results in increased abundance of Dinoprostone]; resveratrol inhibits the reaction [APP protein results in increased secretion of Dinoprostone] Dinoprostone results in increased expression of APP protein modified form |
CTD |
PMID:16685418 PMID:20171164 PMID:23261590 PMID:28721267 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
increases response to substance |
ISO |
AQP1 results in increased susceptibility to Dinoprostone |
CTD |
PMID:20018876 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Areg |
amphiregulin |
increases expression multiple interactions |
ISO EXP |
Dinoprostone results in increased expression of AREG mRNA; Dinoprostone results in increased expression of AREG protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of AREG mRNA]; U 0126 inhibits the reaction [Dinoprostone results in increased expression of AREG mRNA] |
CTD |
PMID:15284208 PMID:15509566 PMID:16888076 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions increases phosphorylation |
ISO |
[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]]; Dinoprostone promotes the reaction [ATF1 protein modified form binds to PTGS2 promoter]; Ketoconazole inhibits the reaction [Dinoprostone promotes the reaction [ATF1 protein modified form binds to PTGS2 promoter]]; Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein] |
CTD |
PMID:12164941 PMID:22188298 |
|
NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression multiple interactions |
ISO |
Dinoprostone results in increased expression of ATF3 protein ATF3 protein affects the reaction [Dinoprostone results in decreased expression of SIRT1 mRNA]; ATF3 protein affects the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; Dinoprostone promotes the reaction [ATF3 protein binds to SIRT1 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of ATF3 protein] |
CTD |
PMID:30409902 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Avp |
arginine vasopressin |
increases abundance multiple interactions |
EXP |
AVP protein results in increased abundance of Dinoprostone Dexamethasone inhibits the reaction [AVP protein results in increased abundance of Dinoprostone] |
CTD |
PMID:4030047 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of BAK1 protein]] |
CTD |
PMID:25432964 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
[BAX binds to Dinoprostone] which results in increased localization of BAX Dinoprostone inhibits the reaction [Puromycin Aminonucleoside results in increased expression of BAX protein] |
CTD |
PMID:16396944 PMID:17369862 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
Dinoprostone results in increased expression of BCL2 protein Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of BCL2 protein]] |
CTD |
PMID:9443418 PMID:25432964 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
Dinoprostone affects the reaction [Puromycin Aminonucleoside results in decreased expression of BCL2L1 protein] |
CTD |
PMID:16396944 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
increases expression |
ISO |
Dinoprostone results in increased expression of BIRC3 protein |
CTD |
PMID:12837940 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [[Indomethacin results in decreased activity of PTGS2 protein] which results in decreased expression of BIRC5 protein] |
CTD |
PMID:21268125 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
[KNG1 protein co-treated with Dinoprostone] results in increased secretion of CALCA protein; Dinoprostone inhibits the reaction [Flurbiprofen inhibits the reaction [Histamine results in increased secretion of CALCA protein]]; Dinoprostone inhibits the reaction [Flurbiprofen inhibits the reaction [Serotonin results in increased secretion of CALCA protein]]; Dinoprostone promotes the reaction [Capsaicin results in increased secretion of CALCA protein]; Dinoprostone promotes the reaction [Protons results in increased secretion of CALCA protein] |
CTD |
PMID:11166334 PMID:12044622 PMID:14991081 PMID:18296611 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Casp3 |
caspase 3 |
decreases activity multiple interactions |
ISO EXP |
Dinoprostone results in decreased activity of CASP3 protein Dinoprostone inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP3 protein] Dinoprostone inhibits the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein] Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; Dinoprostone inhibits the reaction [SIRT1 mutant form promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]] |
CTD |
PMID:12837940 PMID:16396944 PMID:20335659 PMID:25094029 PMID:25432964 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased cleavage of CASP8 protein]] |
CTD |
PMID:25432964 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP9 protein] |
CTD |
PMID:25094029 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases abundance |
EXP ISO |
CAT protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone] Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA]] N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [CAT protein results in decreased abundance of Dinoprostone] |
CTD |
PMID:10899936 PMID:11286988 PMID:25432964 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbs |
cystathionine beta synthase |
multiple interactions |
ISO |
CBS protein inhibits the reaction [Rotenone results in increased abundance of Dinoprostone] |
CTD |
PMID:25086357 |
|
NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
multiple interactions |
ISO |
[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; CCL12 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of CCL12 mRNA] |
CTD |
PMID:28434932 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
increases expression |
ISO |
Dinoprostone results in increased expression of CCL17 mRNA |
CTD |
PMID:16303787 |
|
NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
ISO |
Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]] Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of CCL2 protein]] Dinoprostone results in decreased expression of CCL2 mRNA |
CTD |
PMID:16303787 PMID:16784723 PMID:21913898 PMID:25432964 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions |
ISO |
[Dinoprostone co-treated with IL1B] results in increased expression of CCL20; Dinoprostone promotes the reaction [IL23A results in increased expression of CCL20]; IL23A promotes the reaction [[Dinoprostone co-treated with IL1B] results in increased expression of CCL20] Dinoprostone inhibits the reaction [rofecoxib results in increased expression of CCL20 mRNA]; Dinoprostone inhibits the reaction [rofecoxib results in increased expression of CCL20 protein] |
CTD |
PMID:17667525 PMID:19273625 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
increases expression |
ISO |
Dinoprostone results in increased expression of CCL22 mRNA |
CTD |
PMID:16303787 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl27 |
C-C motif chemokine ligand 27 |
multiple interactions |
ISO |
Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]] |
CTD |
PMID:16784723 |
|
NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions decreases expression |
ISO |
Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]] Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Dinoprostone inhibits the reaction [rofecoxib results in increased expression of CCL3 protein] Dinoprostone results in decreased expression of CCL3 mRNA |
CTD |
PMID:9863660 PMID:16303787 PMID:17667525 PMID:21913898 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression multiple interactions |
ISO |
Dinoprostone results in decreased expression of CCL4 protein Dinoprostone results in decreased expression of CCL4 mRNA Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]]]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL4 protein]] |
CTD |
PMID:16303787 PMID:17667525 PMID:21913898 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression multiple interactions |
ISO |
Dinoprostone results in decreased expression of CCL5 mRNA Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]] Dinoprostone inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; Dinoprostone inhibits the reaction [rofecoxib results in increased expression of CCL5 mRNA]; Dinoprostone inhibits the reaction [rofecoxib results in increased expression of CCL5 protein]; Dinoprostone inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] |
CTD |
PMID:10495789 PMID:16303787 PMID:16784723 PMID:17667525 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions |
ISO |
[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA] |
CTD |
PMID:28434932 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression |
ISO |
taiwanin C inhibits the reaction [Dinoprostone results in increased expression of CCND1 protein] |
CTD |
PMID:30884126 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
decreases expression |
ISO |
Dinoprostone results in decreased expression of CCR5 mRNA; Dinoprostone results in decreased expression of CCR5 protein |
CTD |
PMID:16303787 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
multiple interactions |
ISO |
[Dinoprostone co-treated with IL1B co-treated with IL23A] affects the expression of CCR6 |
CTD |
PMID:19273625 |
|
NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
increases expression multiple interactions |
ISO |
Dinoprostone results in increased expression of CCR7 mRNA; Dinoprostone results in increased expression of CCR7 protein [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein |
CTD |
PMID:16303787 PMID:18952292 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [Carbon Tetrachloride results in increased expression of CD68 protein] |
CTD |
PMID:25432964 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression multiple interactions |
ISO |
Dinoprostone results in decreased expression of CDH1 protein cryptotanshinone inhibits the reaction [Dinoprostone results in decreased expression of CDH1 protein] |
CTD |
PMID:30208247 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of CEBPA protein]] |
CTD |
PMID:25432964 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions increases secretion |
EXP ISO |
bifenthrin analog inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]; bifenthrin inhibits the reaction [CGA protein results in increased secretion of Dinoprostone] butylbenzyl phthalate inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]; Dibutyl Phthalate inhibits the reaction [CGA protein results in increased secretion of Dinoprostone]; Diethylhexyl Phthalate inhibits the reaction [CGA protein results in increased secretion of Dinoprostone] |
CTD |
PMID:21251947 PMID:21871944 PMID:25016925 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
Dinoprostone results in increased expression of COL10A1 mRNA; Dinoprostone results in increased expression of COL10A1 protein |
CTD |
PMID:27050768 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
Dinoprostone results in decreased expression of COL1A1 mRNA |
CTD |
PMID:8971655 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
increases expression multiple interactions |
ISO EXP |
Dinoprostone results in increased expression of COL2A1 mRNA; Dinoprostone results in increased expression of COL2A1 protein Indomethacin inhibits the reaction [COL2A1 protein results in increased secretion of Dinoprostone]; lupeol inhibits the reaction [COL2A1 protein results in increased secretion of Dinoprostone] |
CTD |
PMID:27050768 PMID:35446470 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cp |
ceruloplasmin |
increases secretion |
EXP |
CP protein results in increased secretion of Dinoprostone |
CTD |
PMID:17727827 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions increases phosphorylation |
ISO |
[nickel sulfate co-treated with Dinoprostone] results in increased expression of CREB1 protein; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]]; CREB1 protein promotes the reaction [[nickel sulfate co-treated with Dinoprostone] results in increased secretion of CXCL8 protein]; Dinoprostone promotes the reaction [CREB1 protein modified form binds to PTGS2 promoter]; Ketoconazole inhibits the reaction [Dinoprostone promotes the reaction [CREB1 protein modified form binds to PTGS2 promoter]]; Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:12164941 PMID:23526216 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
EXP |
Dinoprostone promotes the reaction [arsenite results in increased expression of CRYAB mRNA]; Dinoprostone promotes the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:9066782 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
CSF2 protein promotes the reaction [Dinoprostone results in increased expression of [IL12B protein binds to IL23A protein]] [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein |
CTD |
PMID:15180965 PMID:18952292 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases localization increases expression multiple interactions |
ISO |
Dinoprostone results in increased localization of CTNNB1 protein Dinoprostone results in increased expression of CTNNB1 protein cryptotanshinone inhibits the reaction [Dinoprostone results in increased expression of CTNNB1 protein] |
CTD |
PMID:18395713 PMID:30208247 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]]]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of CXCL10 protein]] |
CTD |
PMID:21913898 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
Dinoprostone results in increased expression of CXCR4 mRNA; Dinoprostone results in increased expression of CXCR4 protein |
CTD |
PMID:16303787 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases expression |
ISO |
Dinoprostone results in increased expression of CYP11A1 mRNA |
CTD |
PMID:19001523 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
Dinoprostone results in increased expression of CYP17A1 mRNA |
CTD |
PMID:19001523 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
multiple interactions increases activity increases expression |
ISO EXP |
2-methoxyoestrone-3-O-sulphamate inhibits the reaction [Dinoprostone results in increased activity of CYP19A1 protein]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; ATF3 protein affects the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; bakuchiol inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; Chlordan inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; Chlordan inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; Dinoprostone inhibits the reaction [NR2F2 protein binds to CYP19A1 promoter]; Dinoprostone inhibits the reaction [WT1 protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [ESRRA protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [ESRRA protein results in increased expression of CYP19A1 mRNA]; Dinoprostone promotes the reaction [ESRRA protein results in increased expression of CYP19A1 protein]; Dinoprostone promotes the reaction [NR5A1 protein binds to CYP19A1 promoter]; ESRRA protein promotes the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; ESRRA protein promotes the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; KAT2B protein affects the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; KAT2B protein affects the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; Resveratrol inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 protein] Dinoprostone results in increased expression of CYP19A1 mRNA; Dinoprostone results in increased expression of CYP19A1 protein |
CTD |
PMID:15862962 PMID:16024248 PMID:19001523 PMID:20351196 PMID:20678559 PMID:23054057 PMID:28571770 PMID:30409902 PMID:31238046 More...
|
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; AH 23848 inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; fulvestrant inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; fulvestrant inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Dinoprostone results in increased expression of CYP1B1 protein] Dinoprostone results in increased expression of CYP1B1 mRNA; Dinoprostone results in increased expression of CYP1B1 protein |
CTD |
PMID:20093341 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Dinoprostone promotes the reaction [DDIT3 protein binds to CXCL8 promoter] |
CTD |
PMID:17709599 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]] |
CTD |
PMID:21911040 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions increases secretion |
EXP ISO |
[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone; Acetaminophen inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone]; nimesulide inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone] EDN1 protein results in increased secretion of Dinoprostone |
CTD |
PMID:16384872 PMID:21811393 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egf |
epidermal growth factor |
multiple interactions increases abundance |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]; Indomethacin promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]] |
CTD |
PMID:17805209 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
increases secretion increases expression multiple interactions increases phosphorylation |
ISO |
EGFR protein results in increased secretion of Dinoprostone Dinoprostone results in increased expression of EGFR protein modified form cryptotanshinone inhibits the reaction [Dinoprostone results in increased expression of EGFR protein modified form]; EGFR mutant form affects the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; EGFR mutant form affects the reaction [lead nitrate results in increased secretion of Dinoprostone] Dinoprostone results in increased phosphorylation of EGFR protein |
CTD |
PMID:16213893 PMID:17805209 PMID:20850495 PMID:30208247 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]; KAT2B protein affects the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; KAT2B protein affects the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]] |
CTD |
PMID:30409902 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
ISO |
EPHX2 gene mutant form affects the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]; EPHX2 gene mutant form promotes the reaction [Aspirin inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]] |
CTD |
PMID:19896470 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Ereg |
epiregulin |
increases expression multiple interactions |
ISO |
Dinoprostone results in increased expression of EREG mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in increased expression of EREG mRNA]; U 0126 inhibits the reaction [Dinoprostone results in increased expression of EREG mRNA] |
CTD |
PMID:16888076 PMID:18444251 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esr1 |
estrogen receptor 1 |
increases phosphorylation |
ISO |
Dinoprostone results in increased phosphorylation of ESR1 protein |
CTD |
PMID:20093341 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions increases expression |
ISO |
6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased expression of ESRRA mRNA]; 6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased expression of ESRRA protein]; Dinoprostone promotes the reaction [ESRRA protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [ESRRA protein promotes the reaction [Testosterone results in increased abundance of Estradiol]]; Dinoprostone promotes the reaction [ESRRA protein results in increased expression of CYP19A1 mRNA]; Dinoprostone promotes the reaction [ESRRA protein results in increased expression of CYP19A1 protein]; ESRRA protein promotes the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; ESRRA protein promotes the reaction [Dinoprostone results in increased expression of CYP19A1 protein] Dinoprostone results in increased expression of ESRRA mRNA; Dinoprostone results in increased expression of ESRRA protein |
CTD |
PMID:20351196 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions increases secretion |
EXP ISO |
[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone; Acetaminophen inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone]; nimesulide inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone] tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased secretion of Dinoprostone]; zinc protoporphyrin inhibits the reaction [tricarbonyldichlororuthenium (II) dimer inhibits the reaction [F2 protein results in increased secretion of Dinoprostone]] |
CTD |
PMID:21811393 PMID:26385185 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression decreases expression |
ISO |
Dinoprostone results in increased expression of FAS Dinoprostone results in decreased expression of FAS mRNA |
CTD |
PMID:10357836 PMID:15491851 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression multiple interactions increases response to substance |
ISO |
Dinoprostone results in increased expression of FASLG Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of FASL protein]] FASLG results in increased susceptibility to Dinoprostone |
CTD |
PMID:15491851 PMID:25432964 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Dinoprostone promotes the reaction [Celecoxib results in decreased activity of FASN protein] |
CTD |
PMID:19159447 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fcer2 |
Fc epsilon receptor II |
decreases expression |
ISO |
Dinoprostone results in decreased expression of FCER2 protein |
CTD |
PMID:1328389 |
|
NCBI chr12:1,742,809...1,754,476
Ensembl chr12:1,742,815...1,754,476
|
|
G |
Fgf20 |
fibroblast growth factor 20 |
increases abundance |
ISO |
FGF20 protein results in increased abundance of Dinoprostone |
CTD |
PMID:12360478 |
|
NCBI chr16:52,030,549...52,038,201
Ensembl chr16:52,010,194...52,038,204
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [FGF23 protein results in increased chemical synthesis of and affects the secretion of Dinoprostone]; FGF23 protein results in increased chemical synthesis of and affects the secretion of Dinoprostone; SB 203580 inhibits the reaction [FGF23 protein results in increased chemical synthesis of and affects the secretion of Dinoprostone] |
CTD |
PMID:16144964 |
|
NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
increases secretion multiple interactions |
EXP |
FGF7 protein results in increased secretion of Dinoprostone Indomethacin inhibits the reaction [FGF7 protein results in increased secretion of Dinoprostone] |
CTD |
PMID:16169897 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Dinoprostone results in increased expression of FOS mRNA |
CTD |
PMID:10864209 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gast |
gastrin |
multiple interactions |
EXP |
Dinoprostone inhibits the reaction [GAST protein results in increased secretion of Histamine] |
CTD |
PMID:11164953 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
increases abundance |
EXP |
GHRL results in increased abundance of Dinoprostone |
CTD |
PMID:16868036 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Glra3 |
glycine receptor, alpha 3 |
multiple interactions increases response to substance |
ISO |
Dinoprostone inhibits the reaction [Excitatory Amino Acid Agents results in increased activity of [PTGER2 protein co-treated with GLRA3 protein]] GLRA3 results in increased susceptibility to Dinoprostone |
CTD |
PMID:15131310 |
|
NCBI chr16:34,199,937...34,848,773
Ensembl chr16:34,204,811...34,848,753
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [Acetaminophen results in increased expression of GPT protein] |
CTD |
PMID:31444509 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of GPX1 mRNA]] |
CTD |
PMID:25432964 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions affects secretion |
ISO |
[GPX2 protein affects the activity of PTGS2 protein] which affects the metabolism of Dinoprostone; [GPX2 protein affects the expression of PTGES protein] which affects the metabolism of Dinoprostone GPX2 protein affects the secretion of Dinoprostone |
CTD |
PMID:18479189 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
increases response to substance |
ISO |
GRIN2A results in increased susceptibility to Dinoprostone |
CTD |
PMID:9113374 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2d |
glutamate ionotropic receptor NMDA type subunit 2D |
increases response to substance |
ISO |
GRIN2D results in increased susceptibility to Dinoprostone |
CTD |
PMID:9113374 |
|
NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793
|
|
G |
Gsk3a |
glycogen synthase kinase 3 alpha |
increases phosphorylation |
ISO |
Dinoprostone results in increased phosphorylation of GSK3A protein |
CTD |
PMID:20578217 |
|
NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation multiple interactions decreases expression |
ISO |
Dinoprostone results in increased phosphorylation of GSK3B protein cryptotanshinone inhibits the reaction [Dinoprostone results in decreased expression of GSK3B protein] |
CTD |
PMID:18395713 PMID:20578217 PMID:30208247 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
affects chemical synthesis |
ISO |
GSTM2 protein affects the chemical synthesis of Dinoprostone |
CTD |
PMID:10905636 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
affects chemical synthesis |
ISO |
GSTM3 protein affects the chemical synthesis of Dinoprostone |
CTD |
PMID:10905636 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
multiple interactions increases abundance |
EXP |
[HCRT results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone HCRT results in increased abundance of Dinoprostone |
CTD |
PMID:18378017 |
|
NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Hgf |
hepatocyte growth factor |
increases abundance |
EXP |
HGF protein results in increased abundance of Dinoprostone |
CTD |
PMID:14751415 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein; [nickel sulfate co-treated with Dinoprostone] results in increased expression of HIF1A protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]; Dinoprostone promotes the reaction [nickel sulfate results in increased expression of and results in increased activity of HIF1A protein]; Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein; HIF1A protein promotes the reaction [[nickel sulfate co-treated with Dinoprostone] results in increased secretion of CXCL8 protein]; HIF1A protein promotes the reaction [[Oxygen deficiency results in increased expression of PTGES protein] which results in increased chemical synthesis of Dinoprostone]; KAT2B protein affects the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]]; KAT2B protein affects the reaction [Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein]; Pertussis Toxin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Resveratrol inhibits the reaction [Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein]; SB 203580 inhibits the reaction [[nickel sulfate co-treated with Dinoprostone] results in increased expression of HIF1A protein]; Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein]; Wortmannin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein] [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of HIF1A mRNA]; HIF1A protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]] |
CTD |
PMID:18832182 PMID:20042640 PMID:20335389 PMID:23526216 PMID:28434932 PMID:30409902 More...
|
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk2 |
hexokinase 2 |
increases expression multiple interactions |
ISO |
Dinoprostone results in increased expression of HK2 mRNA Dinoprostone promotes the reaction [nickel chloride results in increased expression of HK2 mRNA] |
CTD |
PMID:27452194 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
HMOX1 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; HMOX1 protein promotes the reaction [cobaltiprotoporphyrin inhibits the reaction [[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone]] [chromium mesoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [N-bromotaurine results in decreased abundance of Dinoprostone]; [chromium mesoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [N-chlorotaurine results in decreased abundance of Dinoprostone]; Dinoprostone inhibits the reaction [copper protoporphyrin IX promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; Dinoprostone inhibits the reaction [KT 5720 promotes the reaction [Lipopolysaccharides results in increased activity of HMOX1 protein]]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased activity of HMOX1 protein]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]; HMOX1 protein inhibits the reaction [Dimethyl Fumarate inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; HMOX1 protein inhibits the reaction [Probucol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; HMOX1 protein promotes the reaction [IFNG protein results in increased abundance of Dinoprostone]; KT 5720 inhibits the reaction [Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]] |
CTD |
PMID:18157587 PMID:19428335 PMID:22155307 PMID:23942037 PMID:24003391 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
affects abundance multiple interactions increases metabolic processing |
ISO |
HPGD protein affects the abundance of Dinoprostone [Dinoprostone co-treated with NAD] binds to HPGD protein HPGD protein results in increased metabolism of Dinoprostone |
CTD |
PMID:18500342 PMID:19584167 PMID:20448048 PMID:25526675 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions |
ISO |
Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Dinoprostone results in increased abundance of Cyclic AMP] |
CTD |
PMID:9187264 |
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
multiple interactions increases activity |
ISO |
6-isopropoxy-9-oxoxanthene-2-carboxylic acid inhibits the reaction [Dinoprostone results in increased activity of HSD11B1 protein]; Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide promotes the reaction [Dinoprostone results in increased activity of HSD11B1 protein]; Dinoprostone promotes the reaction [HSD11B1 protein affects the oxidation of Hydrocortisone]; PTGER2 protein promotes the reaction [Dinoprostone results in increased activity of HSD11B1 protein] |
CTD |
PMID:17761898 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases activity |
ISO |
Dinoprostone results in decreased activity of HSD11B2 protein |
CTD |
PMID:10377029 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
increases expression |
ISO |
Dinoprostone results in increased expression of HSD3B2 mRNA |
CTD |
PMID:19001523 |
|
NCBI chr 2:186,095,897...186,105,354
Ensembl chr 2:186,095,897...186,101,852
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions increases expression |
ISO |
Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Cadmium Chloride results in increased expression of ICAM1 mRNA]]; Dinoprostone inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Cadmium Chloride results in increased expression of ICAM1 mRNA]]; Dinoprostone inhibits the reaction [Reactive Oxygen Species results in increased expression of ICAM1 mRNA]; Dinoprostone inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] Dinoprostone results in increased expression of ICAM1 mRNA; Dinoprostone results in increased expression of ICAM1 protein |
CTD |
PMID:10495789 PMID:16777358 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions increases abundance decreases expression |
ISO EXP |
2-tert-butylhydroquinone inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; [IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone; [Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; carnosol inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; cobaltiprotoporphyrin inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; Dimethyl Fumarate inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; HMOX1 protein promotes the reaction [IFNG protein results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone]; Mangifera indica extract inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone]; NFE2L2 protein promotes the reaction [IFNG protein results in increased abundance of Dinoprostone]; Probucol inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; Resveratrol inhibits the reaction [IFNG protein results in increased abundance of Dinoprostone]; sulforaphane inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone]; Tetradecanoylphorbol Acetate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; wogonin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Dinoprostone] Dinoprostone results in decreased expression of IFNG protein [IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Dinoprostone; [IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone; Indomethacin inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Dinoprostone]; nimesulide inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Dinoprostone]; sulforaphane inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone] |
CTD |
PMID:9743329 PMID:12911628 PMID:14623498 PMID:15177302 PMID:15788148 PMID:16716910 PMID:19071154 PMID:23362215 PMID:23942037 More...
|
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ighe |
immunoglobulin heavy constant epsilon |
increases expression |
ISO |
Dinoprostone results in increased expression of IGHE protein |
CTD |
PMID:15788148 |
|
|
|
G |
Il10 |
interleukin 10 |
decreases expression increases abundance decreases abundance multiple interactions |
ISO |
Dinoprostone results in decreased expression of IL10; Dinoprostone results in decreased expression of IL10 protein IL10 protein results in increased abundance of Dinoprostone IL10 protein results in decreased abundance of Dinoprostone Dinoprostone promotes the reaction [Zymosan results in increased expression of IL10 mRNA]; Dinoprostone promotes the reaction [Zymosan results in increased expression of IL10 protein]; IL10 gene mutant form promotes the reaction [Silicon Dioxide results in increased abundance of Dinoprostone] Dinoprostone inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10]; IL10 protein inhibits the reaction [Endotoxins results in increased abundance of Dinoprostone]; IL10 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone] |
CTD |
PMID:7582491 PMID:11301049 PMID:12548226 PMID:14975940 PMID:16303787 PMID:19273625 More...
|
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il11 |
interleukin 11 |
multiple interactions increases abundance |
ISO |
Flurbiprofen inhibits the reaction [IL11 protein results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [IL11 protein results in increased abundance of Dinoprostone] |
CTD |
PMID:12110441 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:11369638 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression increases secretion |
ISO |
[TNF protein co-treated with IL1B protein co-treated with Dinoprostone] results in increased expression of IL12B protein; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] Dinoprostone results in increased expression of IL12B protein CSF2 protein promotes the reaction [Dinoprostone results in increased expression of [IL12B protein binds to IL23A protein]]; Dinoprostone results in increased expression of [IL12B protein binds to IL23A protein] Dinoprostone results in increased secretion of IL12B protein Dinoprostone results in increased expression of IL12B mRNA; Dinoprostone results in increased expression of IL12B protein |
CTD |
PMID:10614771 PMID:11369638 PMID:15180965 PMID:16303787 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il12rb1 |
interleukin 12 receptor subunit beta 1 |
decreases expression |
ISO |
Dinoprostone results in decreased expression of IL12RB1 protein |
CTD |
PMID:9743329 |
|
NCBI chr16:18,620,228...18,633,207
Ensembl chr16:18,620,770...18,632,769
|
|
G |
Il12rb2 |
interleukin 12 receptor subunit beta 2 |
decreases expression |
ISO |
Dinoprostone results in decreased expression of IL12RB2 mRNA |
CTD |
PMID:9743329 |
|
NCBI chr 4:96,426,396...96,515,251
Ensembl chr 4:96,426,842...96,515,289
|
|
G |
Il13 |
interleukin 13 |
increases secretion |
ISO |
Dinoprostone results in increased secretion of IL13 protein |
CTD |
PMID:15788148 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il17f |
interleukin 17F |
multiple interactions |
ISO |
[Dinoprostone co-treated with IL23A] results in increased expression of IL17F; Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of IL17F]; Dinoprostone promotes the reaction [IL1B results in increased expression of IL17F] |
CTD |
PMID:19273625 |
|
NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482
|
|
G |
Il17ra |
interleukin 17 receptor A |
multiple interactions |
ISO |
IL17RA gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone] |
CTD |
PMID:22359662 |
|
NCBI chr 4:153,667,534...153,690,174
Ensembl chr 4:153,667,534...153,690,174
|
|
G |
Il1a |
interleukin 1 alpha |
increases abundance multiple interactions increases secretion |
ISO EXP |
IL1A protein results in increased abundance of Dinoprostone mofezolac inhibits the reaction [IL1A protein results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1A protein results in increased abundance of Dinoprostone] [IL1A protein co-treated with Arachidonic Acid] results in increased abundance of Dinoprostone IL1A protein results in increased secretion of Dinoprostone |
CTD |
PMID:8218930 PMID:11351503 PMID:15167967 PMID:16169897 PMID:21513769 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion increases abundance increases expression increases chemical synthesis |
ISO EXP |
1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; 1-Butanol inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]]; [[Oligomycins co-treated with IL1B protein] results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [Dinoprostone co-treated with IL1B co-treated with IL23A] affects the expression of CCR6; [Dinoprostone co-treated with IL1B] results in increased expression of CCL20; [Glucosamine co-treated with Chondroitin Sulfates] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; [IL1B protein co-treated with Oligomycins] results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone; [Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Dinoprostone; [TNF protein co-treated with IL1B protein co-treated with Dinoprostone] results in increased expression of IL12B protein; [Triclosan co-treated with Cetylpyridinium] inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Acetaminophen inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]]; Aspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; BAY 11-7085 inhibits the reaction [[IL1B protein co-treated with Oligomycins] results in increased abundance of Dinoprostone]; Butylated Hydroxyanisole inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Celecoxib promotes the reaction [Aspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; Celecoxib promotes the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; ciglitazone promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; cobaltiprotoporphyrin inhibits the reaction [[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone]; cobaltiprotoporphyrin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; cobaltiprotoporphyrin inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; cordycepin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Dactinomycin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Dactinomycin inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; Dexamethasone inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Dexamethasone inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Dimethyl Sulfoxide inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Dinoprostone inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10]; Dinoprostone inhibits the reaction [Celecoxib inhibits the reaction [IL1B protein results in increased expression of NRG1 mRNA]]; Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of IL17F]; Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of RORC mRNA]; Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; Dinoprostone promotes the reaction [IL1B results in increased expression of IL17F]; Flurbiprofen inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Glucosamine analog inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Glucosamine inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Glucosamine inhibits the reaction [IL1B results in increased abundance of Dinoprostone]; HMOX1 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; HMOX1 protein promotes the reaction [cobaltiprotoporphyrin inhibits the reaction [[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone]]; IL10 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; IL23A promotes the reaction [[Dinoprostone co-treated with IL1B] results in increased expression of CCL20]; Indomethacin inhibits the reaction [[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [IL1B results in increased chemical synthesis of Dinoprostone]; L 745337 inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; licochalcone A inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Naproxen promotes the reaction [Aspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; Naproxen promotes the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Oligomycins promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; prolinedithiocarbamate inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; PTGS1 protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; PTGS2 protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; pyrazolanthrone inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Quercetin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Resveratrol inhibits the reaction [[IL1B protein co-treated with Oligomycins] results in increased abundance of Dinoprostone]; Resveratrol inhibits the reaction [[IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Resveratrol inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; Ro 31-8220 inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; rofecoxib promotes the reaction [Aspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; rofecoxib promotes the reaction [nitroaspirin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with IL1B protein] results in increased abundance of Dinoprostone]]; sargachromanol G inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; sauchinone inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; SB 203580 inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; SC 560 inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Tamoxifen promotes the reaction [Resveratrol inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]]; Triclosan inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone] Dinoprostone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein] IL1B protein results in increased abundance of Dinoprostone; IL1B results in increased abundance of Dinoprostone [IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone; [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]]; morroniside inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; sulforaphane inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone]; Tetradecanoylphorbol Acetate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone] 2-methoxycinnamaldehyde inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; [IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Ketorolac co-treated with IL1B protein] results in increased secretion of Dinoprostone; CAT protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; cinnamaldehyde inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; Dinoprostone analog inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of IL1B protein]; Dinoprostone inhibits the reaction [IL1B protein results in increased abundance of copper bis(3,5-diisopropylsalicylate)]; Glucosamine inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; GW0072 inhibits the reaction [[IL1B protein co-treated with Rosiglitazone] results in increased secretion of Dinoprostone]; IL1B protein promotes the reaction [PTGS2 protein results in increased chemical synthesis of and results in increased secretion of Dinoprostone]; IL1B protein promotes the reaction [Rosiglitazone results in increased secretion of Dinoprostone]; Indomethacin inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1B protein results in increased abundance of Dinoprostone]; pyrrolidine dithiocarbamic acid inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Rotenone inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; sulforaphane inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased abundance of Dinoprostone]; theaflavin-3,3'-digallate inhibits the reaction [IL1B protein results in increased abundance of and results in increased secretion of Dinoprostone] Dinoprostone results in increased expression of IL1B protein |
CTD |
PMID:1515551 PMID:7582491 PMID:8662662 PMID:9266823 PMID:10614771 PMID:10800959 PMID:11112151 PMID:11229466 PMID:11286988 PMID:11530235 PMID:11854442 PMID:11882577 PMID:12512699 PMID:12517972 PMID:12548226 PMID:12681956 PMID:12743569 PMID:12897060 PMID:14623498 PMID:14762100 PMID:15144122 PMID:15180920 PMID:15180965 PMID:16253096 PMID:16354411 PMID:16357062 PMID:16492401 PMID:16529823 PMID:16624280 PMID:17077517 PMID:17605605 PMID:18026701 PMID:18054255 PMID:18759268 PMID:18952292 PMID:19071154 PMID:19273625 PMID:19428335 PMID:19751497 PMID:21878375 PMID:21954917 PMID:22039321 PMID:22089456 PMID:22155307 PMID:22549761 PMID:22592909 PMID:22727857 PMID:24346509 PMID:24609059 PMID:25432964 PMID:27645308 PMID:29356224 PMID:32061760 PMID:33804203 PMID:35847580 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
increases activity increases expression |
ISO |
Dinoprostone results in increased activity of IL1R1 protein Dinoprostone results in increased expression of IL1R1 mRNA |
CTD |
PMID:19273625 PMID:19407222 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [IL1RN protein results in decreased expression of IL6 protein]; IL1RN protein inhibits the reaction [Dinoprostone inhibits the reaction [Indomethacin results in decreased expression of IL6 protein]] |
CTD |
PMID:8520508 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il2 |
interleukin 2 |
decreases expression |
ISO |
Dinoprostone results in decreased expression of IL2; Dinoprostone results in decreased expression of IL2 protein |
CTD |
PMID:2948675 PMID:2989362 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il22 |
interleukin 22 |
decreases expression |
ISO |
Dinoprostone results in decreased expression of IL22 |
CTD |
PMID:19273625 |
|
NCBI chr 7:53,801,206...53,805,673
Ensembl chr 7:53,801,206...53,806,186
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions increases expression |
ISO |
[Dinoprostone co-treated with IL1B co-treated with IL23A] affects the expression of CCR6; [Dinoprostone co-treated with IL23A] results in increased expression of IL17F; Dinoprostone inhibits the reaction [[IL23A co-treated with IL1B] results in increased expression of IL10]; Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of IL17F]; Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of RORC mRNA]; Dinoprostone promotes the reaction [IL23A results in increased expression of CCL20]; IL23A promotes the reaction [[Dinoprostone co-treated with IL1B] results in increased expression of CCL20] Dinoprostone results in increased expression of IL23A protein CSF2 protein promotes the reaction [Dinoprostone results in increased expression of [IL12B protein binds to IL23A protein]]; Dinoprostone results in increased expression of [IL12B protein binds to IL23A protein] Dinoprostone results in increased expression of IL23A mRNA |
CTD |
PMID:15180965 PMID:19273625 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression |
ISO |
Dinoprostone results in decreased expression of IL2RA |
CTD |
PMID:2948675 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il2rg |
interleukin 2 receptor subunit gamma |
decreases expression |
ISO |
Dinoprostone results in decreased expression of IL2RG |
CTD |
PMID:19812686 |
|
NCBI chr X:66,395,330...66,399,026
Ensembl chr X:66,392,542...66,399,823
|
|
G |
Il4 |
interleukin 4 |
increases secretion multiple interactions decreases secretion increases response to substance |
ISO |
Dinoprostone results in increased secretion of IL4 protein; IL4 protein results in increased secretion of Dinoprostone [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein; [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone; amorolfine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; butenafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Itraconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Ketoconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; luliconazole promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone]; Terbinafine promotes the reaction [[Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprostone] IL4 results in decreased secretion of Dinoprostone IL4 protein results in increased susceptibility to Dinoprostone |
CTD |
PMID:12370375 PMID:15788148 PMID:18952292 PMID:19767084 PMID:23688403 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
increases secretion |
ISO |
Dinoprostone results in increased secretion of IL5 protein |
CTD |
PMID:15788148 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
[Dinoprostone co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein; Dinoprostone inhibits the reaction [IL1RN protein results in decreased expression of IL6 protein]; Dinoprostone inhibits the reaction [Indomethacin results in decreased expression of IL6 protein]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Dinoprostone promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; IL1RN protein inhibits the reaction [Dinoprostone inhibits the reaction [Indomethacin results in decreased expression of IL6 protein]] [IL6 protein results in increased expression of PTGES mRNA] which results in increased secretion of and results in increased abundance of Dinoprostone; [IL6 protein results in increased expression of PTGS2 mRNA] which results in increased secretion of and results in increased abundance of Dinoprostone; Celecoxib inhibits the reaction [IL6 protein results in increased secretion of and results in increased abundance of Dinoprostone]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]]; IL6 protein results in increased secretion of and results in increased abundance of Dinoprostone Dinoprostone results in increased expression of IL6 protein Dexamethasone inhibits the reaction [Dinoprostone results in increased expression of IL6 protein]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Lipopolysaccharides promotes the reaction [Dinoprostone results in increased expression of IL6 protein] |
CTD |
PMID:7536779 PMID:8520508 PMID:15180965 PMID:15379866 PMID:16303787 PMID:18952292 PMID:20388727 PMID:21803157 PMID:24285838 PMID:25432964 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irak3 |
interleukin-1 receptor-associated kinase 3 |
increases expression |
ISO |
prostaglandin E2 increases expression of Irak3 protein in alveolar macrophages |
RGD |
PMID:20439918 |
RGD:36049799 |
NCBI chr 7:55,653,949...55,714,371
Ensembl chr 7:55,653,962...55,713,121
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO EXP |
ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]; TRPV4 protein promotes the reaction [ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]] ITGA2 protein results in increased susceptibility to [KNG1 protein modified form co-treated with TAC1 protein modified form co-treated with Serotonin co-treated with Dinoprostone co-treated with Histamine] |
CTD |
PMID:18234883 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases response to substance |
EXP |
ITGB1 results in increased susceptibility to Dinoprostone |
CTD |
PMID:14984413 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Jak3 |
Janus kinase 3 |
multiple interactions |
ISO |
Dinoprostone results in decreased phosphorylation of and results in decreased activity of JAK3 protein |
CTD |
PMID:19812686 |
|
NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
multiple interactions |
ISO |
KAT2B protein affects the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; KAT2B protein affects the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]]; KAT2B protein affects the reaction [Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein]; KAT2B protein affects the reaction [Dinoprostone results in increased expression of CYP19A1 protein] |
CTD |
PMID:30409902 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Kng1 |
kininogen 1 |
increases abundance increases secretion multiple interactions |
EXP |
KNG1 protein alternative form results in increased abundance of Dinoprostone; KNG1 protein results in increased abundance of Dinoprostone KNG1 protein modified form results in increased secretion of Dinoprostone [KNG1 protein co-treated with Dinoprostone] results in increased secretion of CALCA protein; [KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone; [KNG1 protein co-treated with Serotonin co-treated with Histamine] results in increased abundance of Dinoprostone; [Serotonin co-treated with Histamine] promotes the reaction [KNG1 protein results in increased abundance of Dinoprostone]; Acetaminophen inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone]; Dexamethasone inhibits the reaction [KNG1 protein alternative form results in increased abundance of Dinoprostone]; Dinoprostone promotes the reaction [Histamine promotes the reaction [Serotonin promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]]]; Dinoprostone promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]; Flurbiprofen inhibits the reaction [[KNG1 protein co-treated with Serotonin co-treated with Histamine] results in increased abundance of Dinoprostone]; Flurbiprofen inhibits the reaction [[Serotonin co-treated with Histamine] promotes the reaction [KNG1 protein results in increased abundance of Dinoprostone]]; ITGA2 protein results in increased susceptibility to [KNG1 protein modified form co-treated with TAC1 protein modified form co-treated with Serotonin co-treated with Dinoprostone co-treated with Histamine]; nimesulide inhibits the reaction [[KNG1 protein co-treated with F2 protein co-treated with EDN1 protein co-treated with Potassium Chloride] results in increased secretion of Dinoprostone]; Serotonin promotes the reaction [KNG1 protein results in increased abundance of Dinoprostone]; Streptozocin promotes the reaction [KNG1 protein modified form results in increased secretion of Dinoprostone] |
CTD |
PMID:4030047 PMID:11166334 PMID:12791437 PMID:18234883 PMID:20832942 PMID:21811393 More...
|
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions increases expression |
ISO |
Dinoprostone promotes the reaction [nickel chloride results in increased expression of LDHA mRNA] Dinoprostone results in increased expression of LDHA mRNA |
CTD |
PMID:27452194 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Lep |
leptin |
increases abundance increases secretion increases expression |
EXP |
LEP protein results in increased abundance of Dinoprostone Dinoprostone results in increased secretion of LEP protein Dinoprostone results in increased expression of LEP protein |
CTD |
PMID:11060898 PMID:16015682 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map3k8 |
mitogen-activated protein kinase kinase kinase 8 |
multiple interactions |
ISO |
MAP3K8 protein affects the reaction [arsenite results in increased secretion of Dinoprostone] |
CTD |
PMID:19808956 |
|
NCBI chr17:53,382,908...53,403,216
Ensembl chr17:53,383,131...53,403,216
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases activity decreases phosphorylation increases phosphorylation multiple interactions |
ISO EXP |
Dinoprostone results in increased activity of MAPK1 protein Dinoprostone results in decreased phosphorylation of MAPK1 protein Dinoprostone results in increased phosphorylation of MAPK1 protein Dinoprostone affects the reaction [[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein] gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16888076 PMID:17805209 PMID:18030065 PMID:18056380 PMID:19201774 PMID:25234201 PMID:26464283 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
increases activity increases phosphorylation multiple interactions |
ISO EXP |
Dinoprostone results in increased activity of MAPK14 protein Dinoprostone results in increased phosphorylation of MAPK14 protein L-826266 inhibits the reaction [Dinoprostone results in increased activity of MAPK14 protein] |
CTD |
PMID:16644903 PMID:18030065 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases activity decreases phosphorylation increases phosphorylation multiple interactions |
ISO EXP |
Dinoprostone results in increased activity of MAPK3 protein Dinoprostone results in decreased phosphorylation of MAPK3 protein Dinoprostone results in increased phosphorylation of MAPK3 protein Dinoprostone affects the reaction [[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein] gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16888076 PMID:17805209 PMID:18030065 PMID:18056380 PMID:19201774 PMID:25234201 PMID:26464283 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases activity multiple interactions |
ISO |
Dinoprostone results in increased activity of MAPK8 protein L-826266 inhibits the reaction [Dinoprostone results in increased activity of MAPK8 protein] |
CTD |
PMID:16644903 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 mRNA]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 protein] |
CTD |
PMID:25094029 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
[MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of CCN2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of MMP3 mRNA]; MMP3 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]] |
CTD |
PMID:28434932 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions increases secretion |
ISO |
Dinoprostone results in increased expression of MMP9 mRNA; Dinoprostone results in increased expression of MMP9 protein 15-deoxyprostaglandin J2 inhibits the reaction [Dinoprostone results in increased expression of MMP9 mRNA]; 15-deoxyprostaglandin J2 inhibits the reaction [Dinoprostone results in increased secretion of MMP9 protein]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 mRNA]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 protein]; Fenofibrate inhibits the reaction [Dinoprostone results in increased expression of MMP9 mRNA]; Fenofibrate inhibits the reaction [Dinoprostone results in increased secretion of MMP9 protein] |
CTD |
PMID:16330497 PMID:19880272 PMID:25094029 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Dinoprostone analog inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:22039321 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[Sirolimus results in decreased activity of MTOR protein] inhibits the reaction [resveratrol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]] |
CTD |
PMID:22363816 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc1 |
mucin 1, cell surface associated |
multiple interactions |
ISO |
[IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein |
CTD |
PMID:18952292 |
|
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression decreases expression |
ISO EXP |
Dinoprostone results in increased expression of MYC; Dinoprostone results in increased expression of MYC protein Dinoprostone results in decreased expression of MYC |
CTD |
PMID:1315190 PMID:8667251 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases expression multiple interactions |
EXP |
Dinoprostone results in increased expression of MYH7 protein Colforsin inhibits the reaction [Dinoprostone results in increased expression of MYH7 protein] |
CTD |
PMID:18851973 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
NFE2L2 protein inhibits the reaction [Dimethyl Fumarate inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; NFE2L2 protein inhibits the reaction [Probucol inhibits the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone]]; NFE2L2 protein promotes the reaction [IFNG protein results in increased abundance of Dinoprostone]; NFE2L2 protein promotes the reaction [Lipopolysaccharides results in increased abundance of Dinoprostone] |
CTD |
PMID:23942037 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions affects activity |
ISO |
[L-335677 co-treated with 6-isopropoxy-9-oxoxanthene-2-carboxylic acid co-treated with L-826266 co-treated with L-161982] inhibits the reaction [Dinoprostone affects the activity of NFKB1 protein] |
CTD |
PMID:18297109 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of NFKBIA protein; exoenzyme C3, Clostridium botulinum inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of NFKBIA protein] Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased degradation of and results in decreased expression of NFKBIA protein]] |
CTD |
PMID:22188298 PMID:25432964 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases secretion |
EXP |
Acetaminophen affects the reaction [NGF protein results in increased secretion of Dinoprostone]; nimesulide inhibits the reaction [NGF protein results in increased secretion of Dinoprostone] |
CTD |
PMID:21811393 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases response to substance |
ISO EXP |
[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Dinoprostone; honokiol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Dinoprostone] Dinoprostone inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; Dinoprostone inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA] NOS2 results in increased susceptibility to Dinoprostone [Ozone results in increased expression of NOS2 protein] which results in increased abundance of Dinoprostone; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]]; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone] |
CTD |
PMID:11919077 PMID:15491851 PMID:16325209 PMID:16944022 PMID:21147091 PMID:25432964 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppa |
natriuretic peptide A |
increases expression multiple interactions increases abundance |
EXP |
Dinoprostone results in increased expression of NPPA mRNA; Dinoprostone results in increased expression of NPPA protein Colforsin inhibits the reaction [Dinoprostone results in increased expression of NPPA protein] NPPA protein results in increased abundance of Dinoprostone |
CTD |
PMID:3070145 PMID:18030065 PMID:18851973 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
EXP |
Dinoprostone results in increased expression of NPPB mRNA |
CTD |
PMID:18030065 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr2f2 |
nuclear receptor subfamily 2, group F, member 2 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [NR2F2 protein binds to CYP19A1 promoter]; Dinoprostone inhibits the reaction [NR2F2 protein binds to STAR promoter] |
CTD |
PMID:19001523 |
|
NCBI chr 1:124,008,282...124,022,521
Ensembl chr 1:124,009,181...124,022,031
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
increases expression multiple interactions |
ISO |
Dinoprostone results in increased expression of NR4A2 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; [Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA; [Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein; exoenzyme C3, Clostridium botulinum inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein] |
CTD |
PMID:16293616 PMID:22188298 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
multiple interactions |
ISO |
Dinoprostone promotes the reaction [NR5A1 protein binds to CYP19A1 promoter]; Dinoprostone promotes the reaction [NR5A1 protein binds to STAR promoter] |
CTD |
PMID:19001523 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions increases expression |
ISO |
Dinoprostone inhibits the reaction [Celecoxib inhibits the reaction [IL1B protein results in increased expression of NRG1 mRNA]] Dinoprostone results in increased expression of NRG1 mRNA |
CTD |
PMID:16357062 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Orm1 |
orosomucoid 1 |
multiple interactions |
EXP |
Dinoprostone inhibits the reaction [Carbon Tetrachloride results in increased expression of ORM1 mRNA] |
CTD |
PMID:15816358 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Osmr |
oncostatin M receptor |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased expression of OSMR mRNA]] |
CTD |
PMID:25432964 |
|
NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:55,907,132...55,961,262
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
ISO |
PARK7 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]; SB 203580 promotes the reaction [PARK7 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]] |
CTD |
PMID:26691871 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [baohuoside I results in increased cleavage of PARP1 protein] |
CTD |
PMID:19289254 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
multiple interactions increases abundance |
ISO |
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone inhibits the reaction [PDGFA results in increased abundance of Dinoprostone]; Celecoxib inhibits the reaction [PDGFA results in increased abundance of Dinoprostone]; Ibuprofen inhibits the reaction [PDGFA results in increased abundance of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [PDGFA results in increased abundance of Dinoprostone] |
CTD |
PMID:19201774 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pklr |
pyruvate kinase L/R |
decreases expression |
ISO |
Dinoprostone results in decreased expression of PKLR mRNA |
CTD |
PMID:10357836 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
increases expression |
ISO |
Dinoprostone results in increased expression of PLA2G2A protein |
CTD |
PMID:15964894 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; [lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA]; EGFR mutant form affects the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; RTKI cpd inhibits the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone] [Cadmium results in increased activity of PLA2G4A protein] which results in increased abundance of Dinoprostone |
CTD |
PMID:15212812 PMID:15878913 PMID:20850495 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions |
ISO |
PLA2G5 protein promotes the reaction [Zymosan results in increased metabolism of Dinoprostone] |
CTD |
PMID:14761945 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Pld1 |
phospholipase D1 |
multiple interactions |
ISO |
PLD1 protein promotes the reaction [cobaltous chloride results in increased abundance of Dinoprostone] |
CTD |
PMID:17640750 |
|
NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Pld2 |
phospholipase D2 |
multiple interactions |
ISO |
PLD2 protein promotes the reaction [cobaltous chloride results in increased abundance of Dinoprostone] |
CTD |
PMID:17640750 |
|
NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
[[nimesulide results in decreased activity of PTGS2 protein] co-treated with [(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid binds to and results in increased activity of PPARD protein]] results in decreased abundance of Dinoprostone; PPARD protein affects the reaction [[nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone]; PPARD protein mutant form inhibits the reaction [[nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone] |
CTD |
PMID:19748995 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Ppp1r9b |
protein phosphatase 1, regulatory subunit 9B |
multiple interactions decreases expression increases expression |
EXP |
fulvestrant inhibits the reaction [Dinoprostone results in decreased expression of PPP1R9B protein]; PTGER1 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]; PTGER2 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]; PTGER3 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]; PTGER4 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein] |
CTD |
PMID:17408863 PMID:18726914 PMID:23054057 |
|
NCBI chr10:79,938,055...79,954,085
Ensembl chr10:79,938,066...79,954,083
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
ISO |
[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of PRKACA protein |
CTD |
PMID:22188298 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkce |
protein kinase C, epsilon |
affects response to substance |
EXP |
PRKCE protein affects the susceptibility to Dinoprostone |
CTD |
PMID:18509033 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
Dinoprostone promotes the reaction [[Estradiol co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA] |
CTD |
PMID:7506205 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prodh |
proline dehydrogenase |
multiple interactions |
ISO |
[PRODH results in decreased expression of PTGS2] which results in decreased abundance of Dinoprostone |
CTD |
PMID:18794809 |
|
NCBI chr11:82,910,043...82,927,305
Ensembl chr11:82,910,137...82,927,305
|
|
G |
Psen2 |
presenilin 2 |
multiple interactions |
ISO |
[PSEN2 protein mutant form results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone |
CTD |
PMID:16331303 |
|
NCBI chr13:91,967,506...91,993,240
Ensembl chr13:91,967,983...91,993,174
|
|
G |
Pten |
phosphatase and tensin homolog |
increases activity multiple interactions decreases phosphorylation |
EXP |
[[Dinoprostone results in increased activity of RAPGEF3 protein] which results in increased activity of PTPN6 protein] which results in increased activity of PTEN protein; Dinoprostone results in increased activity of PTEN protein dioctanoyl-phosphatidylinositol 4,5-bisphosphate inhibits the reaction [Dinoprostone results in decreased phosphorylation of PTEN protein]; oxodiperoxo(pyridine-2-carboxylate)vanadate(V) inhibits the reaction [Dinoprostone results in increased activity of PTEN protein] |
CTD |
PMID:18056380 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
Dinoprostone binds to and results in increased activity of PTGDR protein; Dinoprostone inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 PMID:27636113 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Ptger1 |
prostaglandin E receptor 1 |
increases response to substance multiple interactions increases activity |
ISO EXP |
PTGER1 protein results in increased susceptibility to Dinoprostone; PTGER1 results in increased susceptibility to Dinoprostone PTGER1 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein] 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; [Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased abundance of Inositol Phosphates; [Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein; [Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein; [Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA; [Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein; [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein; [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of NFKBIA protein; [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of PRKACA protein; [Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Dinoprostone binds to and results in increased activity of PTGER1 protein; exoenzyme C3, Clostridium botulinum inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of NFKBIA protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased expression of NR4A2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of ATF1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein]; Pertussis Toxin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Pertussis Toxin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein]; Sirolimus inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Wortmannin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased expression of HIF1A protein]; Wortmannin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein] Dinoprostone results in increased activity of PTGER1 protein |
CTD |
PMID:11375261 PMID:15126118 PMID:15311063 PMID:17408863 PMID:20335389 PMID:22188298 More...
|
|
NCBI chr19:24,470,258...24,473,687
Ensembl chr19:24,467,532...24,473,559
|
|
G |
Ptger2 |
prostaglandin E receptor 2 |
multiple interactions increases activity increases expression |
ISO EXP |
[[Dinoprostone results in increased activity of PTGER2 protein] which results in increased susceptibility to nickel sulfate] which results in increased secretion of CXCL8 protein; [Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP; [Dinoprostone results in increased activity of PTGER2 protein] which results in increased susceptibility to nickel sulfate; cryptotanshinone inhibits the reaction [Dinoprostone results in increased expression of PTGER2 protein]; Dinoprostone binds to and results in increased activity of PTGER2 protein; Dinoprostone inhibits the reaction [Excitatory Amino Acid Agents results in increased activity of [PTGER2 protein co-treated with GLRA3 protein]]; Endocannabinoids inhibits the reaction [Dinoprostone binds to and results in increased activity of PTGER2 protein]; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER2 protein] which results in increased chemical synthesis of Cyclic AMP]; PTGER2 protein promotes the reaction [Dinoprostone results in increased activity of HSD11B1 protein] PTGER2 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein] |
CTD |
PMID:15131310 PMID:15930264 PMID:17408863 PMID:17709599 PMID:17761898 PMID:23526216 PMID:27636113 PMID:30102254 PMID:30208247 More...
|
|
NCBI chr15:18,215,013...18,228,714
Ensembl chr15:18,217,285...18,228,714
|
|
G |
Ptger3 |
prostaglandin E receptor 3 |
multiple interactions increases expression affects binding increases activity affects response to substance |
ISO EXP |
[Dinoprostone results in increased activity of PTGER3 protein] which results in decreased abundance of Cyclic AMP; Dinoprostone binds to and results in increased activity of PTGER3 protein Dinoprostone binds to and results in increased activity of PTGER3 protein; Endocannabinoids inhibits the reaction [Dinoprostone binds to and results in increased activity of PTGER3 protein] Dinoprostone results in increased expression of PTGER3 mRNA Dinoprostone binds to PTGER3 protein; Dinoprostone binds to PTGER3 protein alternative form PTGER3 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein]; PTGER3 protein affects the reaction [Dinoprostone results in decreased transport of Calcium] PTGER3 affects the susceptibility to Dinoprostone |
CTD |
PMID:10357836 PMID:11375261 PMID:12535167 PMID:14636300 PMID:15937517 PMID:17242161 PMID:17408863 PMID:30102254 More...
|
|
NCBI chr 2:246,606,131...246,750,970
Ensembl chr 2:246,606,183...246,684,434
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
multiple interactions increases expression increases activity |
ISO EXP |
Dinoprostone binds to and results in decreased activity of PTGER4 protein Dinoprostone results in increased expression of PTGER4 protein PTGER4 mutant form inhibits the reaction [Dinoprostone results in increased expression of PPP1R9B protein] Dinoprostone results in increased expression of PTGER4 mRNA [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased susceptibility to nickel sulfate] which results in increased secretion of CXCL8 protein; [Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP; [Dinoprostone results in increased activity of PTGER4 protein] which results in increased susceptibility to nickel sulfate; cryptotanshinone inhibits the reaction [Dinoprostone results in increased expression of PTGER4 protein]; nickel sulfate promotes the reaction [[Dinoprostone results in increased activity of PTGER4 protein] which results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:10800959 PMID:12009843 PMID:17408863 PMID:23526216 PMID:30208247 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptges |
prostaglandin E synthase |
increases abundance multiple interactions |
ISO EXP |
PTGES results in increased abundance of Dinoprostone [Diclofenac results in decreased expression of PTGES mRNA] which results in decreased abundance of Dinoprostone [IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone; [Oxygen deficiency results in increased expression of PTGES protein] which results in increased chemical synthesis of Dinoprostone; cobaltiprotoporphyrin inhibits the reaction [[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone]; HIF1A protein promotes the reaction [[Oxygen deficiency results in increased expression of PTGES protein] which results in increased chemical synthesis of Dinoprostone]; HMOX1 protein promotes the reaction [cobaltiprotoporphyrin inhibits the reaction [[IL1B protein results in increased expression of PTGES protein] which results in increased abundance of Dinoprostone]] [GPX2 protein affects the expression of PTGES protein] which affects the metabolism of Dinoprostone; [IL6 protein results in increased expression of PTGES mRNA] which results in increased secretion of and results in increased abundance of Dinoprostone; [Lithium Chloride results in increased expression of PTGES protein] which results in increased chemical synthesis of Dinoprostone; [Tetrachlorodibenzodioxin results in increased expression of PTGES mRNA] which results in increased chemical synthesis of Dinoprostone; PTGES protein affects the reaction [Tetrachlorodibenzodioxin results in increased abundance of Dinoprostone] |
CTD |
PMID:17369862 PMID:18479189 PMID:19393675 PMID:19428335 PMID:19692487 PMID:20042640 PMID:22430074 PMID:24285838 More...
|
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptges2 |
prostaglandin E synthase 2 |
multiple interactions |
ISO EXP |
2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid inhibits the reaction [[Lipopolysaccharides results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone]; [Lipopolysaccharides results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone 2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid inhibits the reaction [[Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone]; [Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone; PTGES2 promotes the reaction [APP protein modified form results in increased abundance of Dinoprostone] |
CTD |
PMID:19934399 PMID:20171164 |
|
NCBI chr 3:15,690,501...15,697,688
Ensembl chr 3:15,690,501...15,697,688
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions increases chemical synthesis |
ISO EXP |
Indomethacin inhibits the reaction [PTGS1 protein results in increased chemical synthesis of Dinoprostone]; PTGS1 protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone] [resveratrol results in decreased activity of PTGS1 protein] which results in decreased chemical synthesis of Dinoprostone; [SC 560 results in decreased activity of PTGS1 protein] promotes the reaction [[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Dinoprostone]]; [SC 560 results in decreased activity of PTGS1 protein] which results in decreased abundance of Dinoprostone; Dinoprostone results in decreased susceptibility to [resveratrol results in decreased activity of PTGS1 protein] [mofezolac results in decreased activity of PTGS1 protein] which results in decreased abundance of Dinoprostone; [resveratrol results in decreased activity of PTGS1 protein] which results in decreased chemical synthesis of Dinoprostone; [SC 560 results in decreased activity of PTGS1 protein] which results in decreased abundance of Dinoprostone; Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased expression of OSMR mRNA]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of STAT3 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of CAT mRNA]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of CEBPA protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in decreased expression of GPX1 mRNA]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased cleavage of CASP3 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased cleavage of CASP8 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased degradation of and results in decreased expression of NFKBIA protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of BAK1 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of BCL2 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of CCL2 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of FASL protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of TNF protein]] |
CTD |
PMID:10594344 PMID:16354411 PMID:16894348 PMID:19066340 PMID:19751497 PMID:21873648 PMID:25432964 PMID:27050768 More...
|
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases chemical synthesis multiple interactions affects abundance increases expression increases abundance |
ISO EXP |
PTGS2 protein results in increased chemical synthesis of Dinoprostone 1-phenyl-6,7-dihydroxy-isochroman inhibits the reaction [[Lipopolysaccharides results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; 2,2'-azobis(2-amidinopropane) promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[methanandamide results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; 3,4-dihydroxyphenylethanol inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [[lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone]; [4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased abundance of Dinoprostone]; [4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone]; [4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [[Oligomycins co-treated with IL1B protein] results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [amentoflavone results in decreased expression of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [baohuoside I results in decreased expression of PTGS2] which results in decreased abundance of Dinoprostone; [Bupivacaine results in increased expression of PTGS2] which results in increased abundance of Dinoprostone; [Celecoxib analog results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [Celecoxib results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [cumene hydroperoxide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Dronabinol results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone; [Etodolac results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [Fluorouracil results in increased expression of PTGS2 protein] which results in increased abundance of and results in increased secretion of Dinoprostone; [Genistein inhibits the reaction [Fluorouracil results in increased expression of PTGS2 protein]] which results in decreased abundance of Dinoprostone; [Hydrogen Peroxide results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B protein results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [L 745337 results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone; [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased abundance of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of and results in increased secretion of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Melitten results in decreased expression of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [Meloxicam results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [methanandamide results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [nickel sulfate co-treated with Dinoprostone] results in increased expression of PTGS2 protein; [nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [o,p'-DDT results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Particulate Matter results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone; [PRODH results in decreased expression of PTGS2] which results in decreased abundance of Dinoprostone; [PSEN2 protein mutant form results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [PTGS2 co-treated with Dinoprostone] results in increased expression of VEGFA; [PTGS2 protein results in increased chemical synthesis of Dinoprostone] which results in decreased susceptibility to Fenretinide; [PTGS2 protein results in increased chemical synthesis of Dinoprostone] which results in decreased susceptibility to Tamoxifen; [rofecoxib results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [SC 791 results in decreased activity of PTGS2 protein] inhibits the reaction [cholesterol-3-beta,5-alpha, 6-beta-triol results in increased abundance of Dinoprostone]; [Tetradecanoylphorbol Acetate results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [TGFB1 results in increased expression of PTGS2] which results in increased abundance of Dinoprostone; [TLR2 results in increased expression of PTGS2] which results in increased chemical synthesis of Dinoprostone; [Tobacco Smoke Pollution results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Vehicle Emissions results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone; acadesine inhibits the reaction [[Fluorouracil results in increased expression of PTGS2 protein] which results in increased abundance of and results in increased secretion of Dinoprostone]; arzanol inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Bee Venoms inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]]; Celecoxib inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Dexamethasone inhibits the reaction [[Particulate Matter results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Dexamethasone inhibits the reaction [[Vehicle Emissions results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; Dexamethasone inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Dinoprostone inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Dinoprostone promotes the reaction [ATF1 protein modified form binds to PTGS2 promoter]; Dinoprostone promotes the reaction [CREB1 protein modified form binds to PTGS2 promoter]; Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; Dinoprostone promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; DUSP1 mutant form inhibits the reaction [trichostatin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]]; Etodolac inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Flurbiprofen inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Flurbiprofen inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; Flurbiprofen inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]; Histamine promotes the reaction [[TLR2 results in increased expression of PTGS2] which results in increased chemical synthesis of Dinoprostone]; Ibuprofen inhibits the reaction [PTGS2 protein affects the chemical synthesis of and affects the abundance of Dinoprostone]; Ketoconazole inhibits the reaction [Dinoprostone promotes the reaction [ATF1 protein modified form binds to PTGS2 promoter]]; Ketoconazole inhibits the reaction [Dinoprostone promotes the reaction [CREB1 protein modified form binds to PTGS2 promoter]]; Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]; Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]; Ketoprofen inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; lucidone inhibits the reaction [2,2'-azobis(2-amidinopropane) promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; manoalide inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; nimesulide inhibits the reaction [PTGS2 protein affects the chemical synthesis of and affects the abundance of Dinoprostone]; oleuropein inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; PTGS2 protein affects the chemical synthesis of and affects the abundance of Dinoprostone; PTGS2 protein promotes the reaction [IL1B protein results in increased abundance of Dinoprostone]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Quercetin inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[Hydrogen Peroxide results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of and results in increased secretion of Dinoprostone]; Resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; RTKI cpd inhibits the reaction [[lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone]; SB 203580 inhibits the reaction [[methanandamide results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; scalaradial inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]]; trichostatin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone] [DuP 697 results in decreased expression of PTGS2] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of Dinoprostone]; [HCRT results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [IL1B protein results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Dinoprostone]; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased secretion of Dinoprostone; [nimesulide results in decreased expression of PTGS2 protein] which results in decreased abundance of Dinoprostone; [o,p'-DDT results in decreased expression of PTGS2 mRNA] which results in decreased abundance of Dinoprostone; [PAR-1-activating peptide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [rofecoxib results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [SC 560 results in decreased activity of PTGS1 protein] promotes the reaction [[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] inhibits the reaction [[sodium bisulfite co-treated with sodium sulfite] results in increased abundance of Dinoprostone]]; [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; ciglitazone promotes the reaction [[PAR-1-activating peptide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Dinoprostone inhibits the reaction [Indomethacin results in increased expression of PTGS2]; Dinoprostone results in decreased susceptibility to [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein]; Dinoprostone results in decreased susceptibility to [rofecoxib results in decreased activity of PTGS2 protein]; endotoxin, Escherichia coli promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Ibuprofen inhibits the reaction [endotoxin, Escherichia coli promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; Ibuprofen inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; IL1B protein promotes the reaction [PTGS2 protein results in increased chemical synthesis of and results in increased secretion of Dinoprostone]; lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Meloxicam inhibits the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; PTGS2 protein results in increased chemical synthesis of and results in increased secretion of Dinoprostone; pyrrolidine dithiocarbamic acid inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Rotenone inhibits the reaction [[IL1B protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Troglitazone inhibits the reaction [[PAR-1-activating peptide results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; wuzi yanzong analog inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone] PTGS2 protein affects the abundance of Dinoprostone metabolite Dinoprostone results in increased expression of [IL1B protein results in increased expression of PTGS2 protein]; Dinoprostone results in increased expression of PTGS2 mRNA; Dinoprostone results in increased expression of PTGS2 protein PTGS2 protein mutant form results in increased abundance of Dinoprostone metabolite; PTGS2 protein results in increased abundance of Dinoprostone [Thiamine deficiency results in increased expression of PTGS2 mRNA] which results in increased expression of Dinoprostone 3-caffeoyl-4-dicaffeoylquinic acid inhibits the reaction [phorbolol myristate acetate promotes the reaction [PTGS2 protein results in increased abundance of Dinoprostone]]; 4-hydroxyphenylethanol inhibits the reaction [[Lipids results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one analog inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]] which results in decreased abundance of Dinoprostone; [5,6,7-trimethoxyflavone inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein]] which results in decreased abundance of Dinoprostone; [[Aspirin co-treated with Hydrochloric Acid] results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [[nimesulide results in decreased activity of PTGS2 protein] co-treated with [(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid binds to and results in increased activity of PPARD protein]] results in decreased abundance of Dinoprostone; [Acetaminophen results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone; [Cadmium Chloride results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; [Cadmium results in increased activity of PTGS2 protein] which results in increased abundance of Dinoprostone; [Cadmium results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; [Celecoxib results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [GPX2 protein affects the activity of PTGS2 protein] which affects the metabolism of Dinoprostone; [IL6 protein results in increased expression of PTGS2 mRNA] which results in increased secretion of and results in increased abundance of Dinoprostone; [KT 5720 co-treated with Dinoprostone] inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; [Lipids results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased abundance of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone; [Melitten results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [Mycoplasma arthritidis mitogen results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone; [Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [nonylphenol results in increased expression of and results in increased activity of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [o,p'-DDT results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [prunetin results in decreased expression of PTGS2 mRNA] which results in decreased chemical synthesis of Dinoprostone; [PTGS2 gene mutant form results in increased susceptibility to Kainic Acid] which results in increased abundance of Dinoprostone; [soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone; [sulindac sulfone results in decreased expression of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [TNF protein results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; [Zymosan results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; Acetylcysteine inhibits the reaction [[Cadmium Chloride results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone]; Bee Venoms inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Bee Venoms inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Bee Venoms inhibits the reaction [[TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Caffeine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Capsaicin inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; capsazepine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Carthamus yellow inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Dinoprostone inhibits the reaction [[Indomethacin results in decreased activity of PTGS2 protein] which results in decreased expression of BIRC5 protein]; Dinoprostone inhibits the reaction [[Indomethacin results in decreased activity of PTGS2 protein] which results in decreased phosphorylation of STAT3 protein]; Dinoprostone inhibits the reaction [copper protoporphyrin IX inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; Dinoprostone inhibits the reaction [helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased expression of PTGS2 protein]]; Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]]; Dinoprostone promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; Drugs, Chinese Herbal inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Eugenol inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased abundance of Dinoprostone]; flavokawain A inhibits the reaction [Lipopolysaccharides promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; Flurbiprofen inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; Glucosamine inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased secretion of Dinoprostone]; IL17RA gene mutant form inhibits the reaction [[Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [[soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone]; Lipopolysaccharides promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Melitten inhibits the reaction [[TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; nimesulide inhibits the reaction [[soluble tachyzoite antigen, Toxoplasma gondii results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone]; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; phorbolol myristate acetate promotes the reaction [PTGS2 protein results in increased abundance of Dinoprostone]; piperine inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]]; Plant Extracts inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; PPARD protein affects the reaction [[nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone]; PPARD protein mutant form inhibits the reaction [[nimesulide results in decreased activity of PTGS2 protein] which results in decreased abundance of Dinoprostone]; pyrazolanthrone inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; pyrazolanthrone inhibits the reaction [[Nitroprusside results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Resveratrol inhibits the reaction [[Lipids results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; S-methylisothiopseudouronium inhibits the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; SB 203580 inhibits the reaction [[Cadmium Chloride results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone]; SB 203580 inhibits the reaction [[Cadmium Chloride results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; Selenium deficiency promotes the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Tetradecanoylphorbol Acetate promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprostone]; withaferin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone] |
CTD |
PMID:7575673 PMID:8621535 PMID:8662662 PMID:9266823 PMID:9321948 PMID:9576062 PMID:9705326 PMID:10491155 PMID:10594344 PMID:10791687 PMID:11094054 PMID:11095985 PMID:11112151 PMID:11118042 PMID:11133817 PMID:11286988 PMID:11405284 PMID:11454666 PMID:11500931 PMID:11527419 PMID:11530235 PMID:11743745 PMID:11821123 PMID:11854442 PMID:11882577 PMID:11978490 PMID:11997384 PMID:12144868 PMID:12164941 PMID:12417326 PMID:12517972 PMID:12757841 PMID:12821125 PMID:14530214 PMID:14687664 PMID:14972014 PMID:14984594 PMID:15212812 PMID:15236176 PMID:15242784 PMID:15529353 PMID:15753380 PMID:15878913 PMID:15896711 PMID:16004971 PMID:16127422 PMID:16194365 PMID:16325209 PMID:16331303 PMID:16396944 PMID:16489006 PMID:16529823 PMID:16777358 PMID:16804302 PMID:16894348 PMID:16997862 PMID:17067557 PMID:17570326 PMID:17651055 PMID:17767925 PMID:18081942 PMID:18165598 PMID:18187276 PMID:18297109 PMID:18305957 PMID:18378017 PMID:18479189 PMID:18481165 PMID:18485224 PMID:18507870 PMID:18759268 PMID:18794809 PMID:18805435 PMID:18832182 PMID:18834901 PMID:18840457 PMID:19289254 PMID:19397918 PMID:19428335 PMID:19616084 PMID:19748995 PMID:19751497 PMID:19758985 PMID:19931518 PMID:19954759 PMID:20040740 PMID:20558268 PMID:20678559 PMID:20737476 PMID:20844277 PMID:20848677 PMID:20850495 PMID:20933508 PMID:20954072 PMID:21147091 PMID:21177414 PMID:21268125 PMID:21269535 PMID:21396905 PMID:21873648 PMID:21893401 PMID:21911040 PMID:21913898 PMID:22101131 PMID:22306367 PMID:22359662 PMID:22542552 PMID:22549761 PMID:22595400 PMID:22771391 PMID:22974838 PMID:23110475 PMID:23209616 PMID:23597450 PMID:23712098 PMID:23727179 PMID:24003391 PMID:24161485 PMID:24285838 PMID:25432964 PMID:26464283 PMID:27050768 PMID:36049621 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn6 |
protein tyrosine phosphatase, non-receptor type 6 |
increases activity |
EXP |
[[Dinoprostone results in increased activity of RAPGEF3 protein] which results in increased activity of PTPN6 protein] which results in increased activity of PTEN protein; [Dinoprostone results in increased activity of RAPGEF3 protein] which results in increased activity of PTPN6 protein |
CTD |
PMID:18056380 |
|
NCBI chr 4:157,526,034...157,550,783
Ensembl chr 4:157,526,035...157,550,984
|
|
G |
Rapgef3 |
Rap guanine nucleotide exchange factor 3 |
increases activity |
EXP |
[[Dinoprostone results in increased activity of RAPGEF3 protein] which results in increased activity of PTPN6 protein] which results in increased activity of PTEN protein; [Dinoprostone results in increased activity of RAPGEF3 protein] which results in increased activity of PTPN6 protein; Dinoprostone results in increased activity of RAPGEF3 protein |
CTD |
PMID:18056380 |
|
NCBI chr 7:128,875,772...128,898,203
Ensembl chr 7:128,875,773...128,898,521
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dinoprostone co-treated with PTGER1 protein] results in increased phosphorylation of RELA protein] Dinoprostone inhibits the reaction [copper protoporphyrin IX inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]]; Dinoprostone promotes the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:22188298 PMID:24003391 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
multiple interactions |
ISO |
[Sodium, Dietary deficiency results in increased susceptibility to Dinoprostone] which results in increased secretion of REN protein |
CTD |
PMID:10432392 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Retn |
resistin |
increases secretion |
ISO |
RETN protein results in increased secretion of Dinoprostone |
CTD |
PMID:23827175 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Rorc |
RAR-related orphan receptor C |
increases expression multiple interactions |
ISO |
Dinoprostone results in increased expression of RORC Dinoprostone promotes the reaction [[IL1B co-treated with IL23A] results in increased expression of RORC mRNA] |
CTD |
PMID:19273625 |
|
NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907
|
|
G |
Rps6 |
ribosomal protein S6 |
multiple interactions |
ISO |
[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein; Pertussis Toxin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein]; wortmannin inhibits the reaction [[Dinoprostone binds to and results in increased activity of PTGER1 protein] which results in increased phosphorylation of RPS6 protein] |
CTD |
PMID:20335389 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
ISO |
Dinoprostone results in increased expression of RUNX2 mRNA; Dinoprostone results in increased expression of RUNX2 protein |
CTD |
PMID:27050768 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
Dinoprostone inhibits the reaction [SIRT1 mutant form promotes the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]] Dinoprostone results in decreased expression of SIRT1 mRNA; Dinoprostone results in decreased expression of SIRT1 protein 1-(4-fluorobenzoyl)-3-(((6-methoxy-2-naphthyl)oxy)methyl)azetidine-3-carboxylic acid inhibits the reaction [Dinoprostone results in decreased expression of SIRT1 protein]; 4-(4-cyano-2-(2-(4-fluoronaphthalen-1-yl)propionylamino)phenyl)butyric acid inhibits the reaction [Dinoprostone results in decreased expression of SIRT1 protein]; ATF3 protein affects the reaction [Dinoprostone results in decreased expression of SIRT1 mRNA]; Dinoprostone promotes the reaction [ATF3 protein binds to SIRT1 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dinoprostone results in decreased expression of SIRT1 protein]; SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [EP300 protein binds to CYP19A1 promoter]]; SIRT1 protein inhibits the reaction [Dinoprostone promotes the reaction [HIF1A protein binds to EP300 protein]]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of and results in increased acetylation of HIF1A protein]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 mRNA]; SIRT1 protein inhibits the reaction [Dinoprostone results in increased expression of CYP19A1 protein]; SIRT1 protein promotes the reaction [Resveratrol inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]] |
CTD |
PMID:20335659 PMID:20844277 PMID:23257246 PMID:30409902 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
multiple interactions |
ISO |
Dinoprostone promotes the reaction [nickel chloride results in increased expression of SLC16A3 mRNA] |
CTD |
PMID:27452194 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Slc22a22 |
solute carrier family 22 member 22 |
increases transport affects binding |
ISO |
SLC22A22 protein results in increased transport of Dinoprostone Dinoprostone binds to SLC22A22 protein |
CTD |
PMID:20448048 |
|
NCBI chr 7:88,720,425...88,750,111
Ensembl chr 7:88,720,427...88,750,111
|
|
G |
Slc22a6 |
solute carrier family 22 member 6 |
decreases expression |
EXP |
Dinoprostone results in decreased expression of SLC22A6 protein |
CTD |
PMID:19605544 |
|
NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
increases transport increases uptake |
ISO |
SLC22A7 protein results in increased transport of Dinoprostone SLC22A7 protein results in increased uptake of Dinoprostone |
CTD |
PMID:12065749 PMID:15901346 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
increases transport decreases expression affects transport |
ISO EXP |
SLC22A8 protein results in increased transport of Dinoprostone Dinoprostone results in decreased expression of SLC22A8 protein SLC22A8 protein affects the transport of Dinoprostone |
CTD |
PMID:11306713 PMID:15100168 PMID:19605544 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions increases expression |
ISO |
Dinoprostone promotes the reaction [nickel chloride results in increased expression of SLC2A1 mRNA] Dinoprostone results in increased expression of SLC2A1 mRNA |
CTD |
PMID:27452194 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slco2a1 |
solute carrier organic anion transporter family, member 2a1 |
multiple interactions increases transport |
ISO |
Diclofenac inhibits the reaction [SLCO2A1 protein results in increased transport of Dinoprostone]; Indomethacin promotes the reaction [SLCO2A1 protein results in increased transport of Dinoprostone]; Ketoprofen promotes the reaction [SLCO2A1 protein results in increased transport of Dinoprostone]; lumiracoxib inhibits the reaction [SLCO2A1 protein results in increased transport of Dinoprostone]; Naproxen promotes the reaction [SLCO2A1 protein results in increased transport of Dinoprostone] |
CTD |
PMID:19843975 |
|
NCBI chr 8:103,588,916...103,672,546
Ensembl chr 8:103,588,916...103,672,546
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
SOD2 protein inhibits the reaction [Glucose results in increased chemical synthesis of Dinoprostone] |
CTD |
PMID:14514642 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [Celecoxib inhibits the reaction [Arsenic Trioxide results in increased expression of SOX2 protein]] |
CTD |
PMID:29396848 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
increases expression |
ISO |
Dinoprostone results in increased expression of SOX9 mRNA; Dinoprostone results in increased expression of SOX9 protein |
CTD |
PMID:27050768 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression decreases expression |
ISO |
Dinoprostone inhibits the reaction [NR2F2 protein binds to STAR promoter]; Dinoprostone inhibits the reaction [WT1 protein binds to STAR promoter]; Dinoprostone promotes the reaction [NR5A1 protein binds to STAR promoter] Dinoprostone results in increased expression of STAR mRNA; Dinoprostone results in increased expression of STAR protein Dinoprostone results in decreased expression of STAR mRNA |
CTD |
PMID:19001523 PMID:19253104 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [[Indomethacin results in decreased activity of PTGS2 protein] which results in decreased phosphorylation of STAT3 protein]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of STAT3 protein]] |
CTD |
PMID:21268125 PMID:25432964 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Dinoprostone promotes the reaction [Histamine promotes the reaction [Serotonin promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]]]; Dinoprostone promotes the reaction [Kallidin results in increased secretion of TAC1 protein]; Dinoprostone promotes the reaction [KNG1 protein results in increased secretion of TAC1 protein]; ITGA2 protein results in increased susceptibility to [KNG1 protein modified form co-treated with TAC1 protein modified form co-treated with Serotonin co-treated with Dinoprostone co-treated with Histamine] |
CTD |
PMID:11166334 PMID:16039053 PMID:18234883 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tbx21 |
T-box transcription factor 21 |
decreases expression |
ISO |
Dinoprostone results in decreased expression of TBX21 mRNA |
CTD |
PMID:19273625 |
|
NCBI chr10:82,082,322...82,098,831
Ensembl chr10:82,082,322...82,098,831
|
|
G |
Tfrc |
transferrin receptor |
decreases expression |
ISO |
Dinoprostone results in decreased expression of TFRC protein |
CTD |
PMID:2989362 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression |
ISO EXP |
[TGFB1 results in increased expression of PTGS2] which results in increased abundance of Dinoprostone [CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB1 mRNA] Dinoprostone results in decreased expression of TGFB1 mRNA Dinoprostone inhibits the reaction [Glucose results in increased expression of TGFB1 mRNA] |
CTD |
PMID:8877289 PMID:16489006 PMID:28434932 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions |
ISO |
[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFB2 mRNA] |
CTD |
PMID:28434932 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tgfb3 |
transforming growth factor, beta 3 |
multiple interactions |
ISO |
CCL12 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]]; Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]; HIF1A protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]]; MMP3 protein affects the reaction [Dinoprostone inhibits the reaction [Bleomycin results in increased expression of TGFB3 mRNA]] |
CTD |
PMID:28434932 |
|
NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
multiple interactions |
ISO |
[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR1 mRNA] |
CTD |
PMID:28434932 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Tgfbr2 |
transforming growth factor, beta receptor 2 |
multiple interactions |
ISO |
[CCL12 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; [HIF1A protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA]; [MMP3 protein co-treated with Dinoprostone] affects the reaction [Bleomycin results in increased expression of TGFBR2 mRNA] |
CTD |
PMID:28434932 |
|
NCBI chr 8:115,794,537...115,883,615
Ensembl chr 8:115,794,537...115,883,228
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression |
ISO |
Dinoprostone results in decreased expression of THRSP mRNA |
CTD |
PMID:10357836 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
Dinoprostone results in increased expression of TIMP1 mRNA; Dinoprostone results in increased expression of TIMP1 protein Dinoprostone inhibits the reaction [PTGS1 gene mutant form inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 protein]] |
CTD |
PMID:16330497 PMID:25432964 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
[TLR2 results in increased expression of PTGS2] which results in increased chemical synthesis of Dinoprostone; Histamine promotes the reaction [[TLR2 results in increased expression of PTGS2] which results in increased chemical synthesis of Dinoprostone] |
CTD |
PMID:20040740 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion increases abundance decreases expression |
ISO EXP |
1-carboxyheptylimidazole promotes the reaction [TNF protein results in increased secretion of Dinoprostone]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]]; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of CCR7 protein; [IL4 protein co-treated with CSF2 protein co-treated with TNF protein co-treated with Dinoprostone co-treated with IL1B protein co-treated with IL6 protein] results in increased expression of MUC1 protein; [Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Dinoprostone; [TNF protein co-treated with IL1B protein co-treated with Dinoprostone] results in increased expression of IL12B protein; [Triclosan co-treated with Cetylpyridinium] inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; cyanidin-3-O-beta-glucopyranoside inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [Ketoconazole inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 mRNA]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL27 protein]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]]; Dinoprostone deficiency inhibits the reaction [Terbinafine inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Dinoprostone inhibits the reaction [3,4-dihydroxyphenylethanol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; Dinoprostone inhibits the reaction [3,4-dihydroxyphenylethanol promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; Dinoprostone inhibits the reaction [Indomethacin inhibits the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Dinoprostone promotes the reaction [Roflumilast inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; Dinoprostone promotes the reaction [roflumilast N-oxide inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]]; Indomethacin inhibits the reaction [[Lipopolysaccharides co-treated with IL1B protein co-treated with TNF protein] results in increased abundance of Dinoprostone]; Indomethacin inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Ketoconazole promotes the reaction [TNF protein results in increased secretion of Dinoprostone]; pyrrolidine dithiocarbamic acid promotes the reaction [rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]]; Resveratrol inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; rhodojaponin II inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]]; sorbinil inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; Terbinafine promotes the reaction [TNF protein results in increased secretion of Dinoprostone]; Triclosan inhibits the reaction [TNF protein results in increased metabolism of Dinoprostone]; Triclosan inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; wedelolactone inhibits the reaction [TNF protein results in increased abundance of Dinoprostone] TNF protein results in increased abundance of Dinoprostone; TNF protein results in increased abundance of Dinoprostone metabolite Dinoprostone results in decreased expression of TNF protein Benzo(a)pyrene promotes the reaction [TNF protein results in increased abundance of Dinoprostone]; Dexamethasone inhibits the reaction [TNF protein results in increased abundance of Dinoprostone metabolite]; Dexamethasone inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Dinoprostone analog inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of TNF protein]; Dinoprostone inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; TNF protein promotes the reaction [Benzo(a)pyrene results in increased abundance of Dinoprostone] [TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone; [TNF protein results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone; [TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Aspirin inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Aspirin inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; Bee Venoms inhibits the reaction [[TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; Curcumin inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Curcumin inhibits the reaction [TNF protein results in increased secretion of Dinoprostone]; Dinoprostone inhibits the reaction [PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased expression of TNF protein]]; Dinoprostone inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; Dinoprostone inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA]; Dinoprostone inhibits the reaction [Zymosan results in increased expression of TNF mRNA]; Dinoprostone inhibits the reaction [Zymosan results in increased expression of TNF protein]; Melitten inhibits the reaction [[TNF protein results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [TNF protein results in increased abundance of Dinoprostone]; Tetradecanoylphorbol Acetate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone] TNF protein results in increased abundance of Dinoprostone; TNF results in increased abundance of Dinoprostone |
CTD |
PMID:1515551 PMID:1993070 PMID:7536779 PMID:9298541 PMID:9576062 PMID:10495789 PMID:10614771 PMID:11301049 PMID:12743569 PMID:14623498 PMID:15379866 PMID:15489888 PMID:15642051 PMID:16253096 PMID:16303787 PMID:16492401 PMID:16754782 PMID:16784723 PMID:17067557 PMID:18054255 PMID:18952292 PMID:19616084 PMID:20388727 PMID:21334316 PMID:21745554 PMID:21803157 PMID:21913898 PMID:22039321 PMID:23257246 PMID:25432964 PMID:25866079 PMID:27793764 PMID:32613688 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions increases secretion increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dinoprostone results in increased secretion of TNFRSF11B protein]; pyrazolanthrone inhibits the reaction [Dinoprostone results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Dinoprostone results in increased secretion of TNFRSF11B protein] Dinoprostone results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:25234201 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases activity |
ISO |
Dinoprostone results in increased activity of TNFRSF1A protein |
CTD |
PMID:19407222 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Trpc7 |
transient receptor potential cation channel, subfamily C, member 7 |
increases response to substance |
ISO |
TRPC7 results in increased susceptibility to Dinoprostone |
CTD |
PMID:16790996 |
|
NCBI chr17:7,708,911...7,833,435
Ensembl chr17:7,709,583...7,833,435
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
multiple interactions |
ISO |
TRPV4 protein promotes the reaction [ITGA2 protein promotes the reaction [[Dinoprostone co-treated with Serotonin] results in increased import of Calcium]] |
CTD |
PMID:18234883 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
EXP |
UCP1 protein inhibits the reaction [Glucose results in increased chemical synthesis of Dinoprostone] |
CTD |
PMID:14514642 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases chemical synthesis |
EXP |
UGT1A1 protein mutant form results in increased chemical synthesis of Dinoprostone |
CTD |
PMID:3864191 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation |
ISO |
Dinoprostone results in increased phosphorylation of VASP protein |
CTD |
PMID:18182247 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[[Cisplatin co-treated with ciglitazone] results in decreased expression of VEGFA] which results in decreased abundance of Dinoprostone; [nickel sulfate co-treated with Dinoprostone] results in increased secretion of VEGFA protein; [PTGS2 co-treated with Dinoprostone] results in increased expression of VEGFA |
CTD |
PMID:12821125 PMID:18832182 PMID:21681689 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
decreases expression |
ISO |
Dinoprostone results in decreased expression of VEGFC mRNA; Dinoprostone results in decreased expression of VEGFC protein |
CTD |
PMID:18509974 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
G |
Vgf |
VGF nerve growth factor inducible |
increases abundance |
EXP |
VGF results in increased abundance of Dinoprostone |
CTD |
PMID:20805684 |
|
NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
ISO |
Dinoprostone inhibits the reaction [WT1 protein binds to CYP19A1 promoter]; Dinoprostone inhibits the reaction [WT1 protein binds to STAR promoter] |
CTD |
PMID:19001523 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
prostaglandin E3 promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:12573452 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
prostaglandin E3 promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:12573452 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
increases metabolic processing |
ISO |
PTGR1 protein results in increased metabolism of prostaglandin F1 analog |
CTD |
PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Lipopolysaccharides results in increased expression of PTGS2 mRNA] which results in increased secretion of prostaglandin F1 |
CTD |
PMID:21913898 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases metabolic processing |
ISO |
AKR1C2 protein results in increased metabolism of Dinoprost |
CTD |
PMID:8573067 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[AKR1C3 protein results in increased reduction of Prostaglandin D2] which results in increased chemical synthesis of Dinoprost; [Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2; Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost] |
CTD |
PMID:19997560 PMID:20036328 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
EXP |
Dinoprost results in increased expression of ANXA4 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
Dinoprost results in increased expression of ATP1A1 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp2b4 |
ATPase plasma membrane Ca2+ transporting 4 |
increases response to substance |
ISO |
ATP2B4 protein results in increased susceptibility to Dinoprost |
CTD |
PMID:12933703 |
|
NCBI chr13:45,156,137...45,255,292
Ensembl chr13:45,156,146...45,255,246
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
CAT protein inhibits the reaction [Dinoprost results in increased expression of PTGS2 mRNA]; CAT protein inhibits the reaction [Dinoprost results in increased localization of RELA protein] |
CTD |
PMID:20826536 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
EXP |
Dinoprost results in decreased expression of CCND2 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis |
ISO |
CES1 protein results in increased hydrolysis of Dinoprost |
CTD |
PMID:21049984 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis |
ISO |
CES2 protein results in increased hydrolysis of Dinoprost |
CTD |
PMID:21049984 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
Dinoprost results in increased expression of COL10A1 mRNA; Dinoprost results in increased expression of COL10A1 protein |
CTD |
PMID:27050768 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
increases expression |
ISO |
Dinoprost results in increased expression of COL2A1 mRNA; Dinoprost results in increased expression of COL2A1 protein |
CTD |
PMID:27050768 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
ISO EXP |
Dinoprost results in decreased expression of CYP19A1 mRNA Dinoprost results in decreased expression of CYP19A1 mRNA; Dinoprost results in decreased expression of CYP19A1 protein Dinoprost promotes the reaction [GATA4 protein binds to CYP19A1 promoter] |
CTD |
PMID:11517196 PMID:15271885 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Dll4 |
delta like canonical Notch ligand 4 |
decreases expression |
EXP |
Dinoprost results in decreased expression of DLL4 mRNA |
CTD |
PMID:21209419 |
|
NCBI chr 3:106,317,114...106,327,004
Ensembl chr 3:106,316,986...106,326,931
|
|
G |
Ereg |
epiregulin |
multiple interactions increases expression |
ISO |
[AL 8810 results in decreased activity of PTGFR protein] inhibits the reaction [[trans-10,cis-12-conjugated linoleic acid results in increased abundance of Dinoprost] which results in increased expression of EREG]; [trans-10,cis-12-conjugated linoleic acid promotes the reaction [PTGS2 protein results in increased chemical synthesis of Dinoprost]] which results in increased expression of EREG; [trans-10,cis-12-conjugated linoleic acid results in increased abundance of Dinoprost] which results in increased expression of EREG Dinoprost results in increased expression of EREG |
CTD |
PMID:22583689 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
EXP |
Dinoprost results in increased expression of ESR1 mRNA |
CTD |
PMID:21654155 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
[Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 mRNA; [Niacin results in decreased abundance of Dinoprost] which results in increased expression of FABP4 protein |
CTD |
PMID:21236357 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions affects localization |
EXP |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Dinoprost affects the localization of [FGF2 protein binds to FGFR2 protein]; Dinoprost promotes the reaction [FGF2 protein binds to FGFR2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGF2 protein] |
CTD |
PMID:15654655 PMID:16365892 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
multiple interactions affects localization decreases expression |
EXP |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Dinoprost affects the localization of FGFR2 protein]; Dinoprost affects the localization of [FGF2 protein binds to FGFR2 protein]; Dinoprost promotes the reaction [FGF2 protein binds to FGFR2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Dinoprost affects the localization of FGFR2 protein] Dinoprost results in decreased expression of FGFR2 mRNA |
CTD |
PMID:15654655 PMID:16365892 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
increases expression |
EXP |
Dinoprost results in increased expression of FOSL2 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Gata4 |
GATA binding protein 4 |
multiple interactions increases activity |
EXP |
Dinoprost promotes the reaction [GATA4 protein binds to CYP19A1 promoter] Dinoprost results in increased activity of GATA4 protein |
CTD |
PMID:15271885 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases response to substance |
ISO |
GPX1 gene mutant form results in increased susceptibility to Dinoprost |
CTD |
PMID:24296279 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
decreases expression |
EXP |
Dinoprost results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases activity decreases expression |
ISO EXP |
Dinoprost results in decreased activity of HSD11B2 protein Dinoprost results in decreased expression of HSD11B2 mRNA |
CTD |
PMID:10377029 PMID:11517196 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
decreases expression |
EXP |
Dinoprost results in decreased expression of ID1 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression |
EXP |
Dinoprost results in decreased expression of ID2 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
decreases expression |
EXP |
Dinoprost results in decreased expression of ID3 mRNA |
CTD |
PMID:11517196 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases abundance |
ISO |
IL10 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprost] IL10 protein results in increased abundance of Dinoprost |
CTD |
PMID:12548226 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
increases abundance |
ISO |
IL1A protein results in increased abundance of Dinoprost |
CTD |
PMID:21513769 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases abundance multiple interactions |
ISO |
IL1B protein results in increased abundance of Dinoprost Dexamethasone inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]; IL10 protein inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]; licochalcone A inhibits the reaction [IL1B protein results in increased abundance of Dinoprost]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [IL1B protein results in increased abundance of Dinoprost] |
CTD |
PMID:12548226 PMID:16354411 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
increases expression |
EXP |
Dinoprost results in increased expression of IL2RA mRNA |
CTD |
PMID:11517196 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Il4 |
interleukin 4 |
increases secretion multiple interactions |
ISO |
IL4 protein results in increased secretion of Dinoprost [Poly I-C co-treated with IL4 protein] results in increased secretion of Dinoprost |
CTD |
PMID:23688403 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Kpnb1 |
karyopherin subunit beta 1 |
increases expression |
EXP |
Dinoprost results in increased expression of KPNB1 protein |
|